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ABSTRACT 
Dissertation under the direction of Keith R. Buszek, Ph.D., Professor of Chemistry, 
University of Missouri-Kansas City. 
Heterocyclic chemistry is one of the most valuable sources of novel compounds with 
diverse biological activity. The indole nucleus for instance, is an important element of many 
natural and synthetic molecules with significant biological activity. Drug discovery and 
development processes highly value the utility of the ability to synthesize a diverse library 
based on one core scaffold which can be screened against a variety of different receptors and 
cell lines, yielding several active compounds. Privileged structures offer an ideal source of 
lead compounds for drug discovery due to their inherent affinity for diverse biological 
targets. Indole motifs represent one of the most prominent privileged structures and are 
ubiquitous in natural products and pharmaceutical compounds. A variety of fused 
heterocyclic structures will be designed, resulting in novel polycyclic frameworks with 
virtually no representation in the National Institutes of Health PubChem and Molecular 
Library of Small Molecule Repository (MLSMR) databases.  
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These molecular frameworks would be predicted to occupy unoccupied or sparsely 
occupied regions of the chemical property space, which increase their chances of finding 
applications as new drug leads with different modes of actions. Consequently, efficient 
methodologies resulting in polycyclic structures from biologically active heterocyclic 
templates are highly desired in the drug discovery and development programs. The synthesis 
of such a unique class of polycyclic benzannulated indole scaffolds is described. 
The 4,6,7-tribromoindole and the 5,6,7-tribromoindole were synthesized via the 
Bartoli and Leimgruber-Batcho and indole synthesis protocols respectively. Both indoles 
underwent selective metal-halogen exchange at C-7 and subsequent elimination to give the 
6,7-indole aryne which underwent Diels-Alder cycloadditions with cyclopentadiene, furan 
and 2,5-dimethyl furan. These cycloadducts were N-alkylated and then subjected to Grubb’s 
catalyst ring opening metathesis/ring closing metathesis to afford 12 unique 6,7-
benzannulated with an additional 7 or 8–membered rings fused from the benzenoid ring to 
the pyrrole ring of the indole nucleus.  
Library development is facilitated by the extra bromine at the 4 or 5 position of the 
indole nucleus which serves as a diversity handle which can be subjected to several 
palladium catalyzed cross-couplings including but not limited to Suzuki-Miyaura, Negishi 
and Buchwald-Hartwig. Diversity of these scaffolds can be further enhanced via olefin 
functionalization: cross metathesis, hydroamination and epoxidation among others to afford 
pharmaceutically useful functional groups like carbamates, ureas, secondary and tertiary 
amines as well as sulfonamides.   
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.1 Arynes and Hetarynes as emerging powerful tools for natural products total 
synthesis and library development 
Arynes and benzynes are interchangeably used terms referring to highly reactive 
species derived from an aromatic ring by various methodologies (Tadross and Stoltz, 2012). 
Arynes are usually postulated as having a strained triple bond although they have been 
demonstrated to also possess some biradical character (Figure 1.1). The most frequently used 
representation of aryne is ortho-benzyne (benzyne, 1.1a). However, the meta (1.1f) and para 
(1.1g) isomers (Figure 1.2) gained interest after the discovery of the enediyne antibiotics, “a 
promising new class of antitumor drugs” (Wenk, Winkler et al., 2003). 
 
Figure 1.1: Canonical representation of benzyne. 
 
Figure 1.2: Ortho-, meta-, para- benzyne respectively. 
Benzyne was first hypothesized by Wittig in 1942 (Wittig, 1942) and a classic carbon 
isotopic labeling experiment (Scheme 1.1) provided the first indirect experimental evidence 
of benzyne’s existence (Roberts, Simmons et al., 1953). 
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• = 14C 
Scheme 1.1: Roberts’ benzyne preparation and labeling experiment. 
Hetarynes or heteroarynes are arynes with a heteroatom, usually nitrogen, oxygen or 
sulfur, as part of the aromatic core. The first proposed existence of a heteroaryne was 
reported in 1902 by Stoermer and Kahlert. They postulated the formation of the reactive 
intermediate; 2,3-didehydrobenzofuran (Figure 1.3, 1.15) (Stoermer and Kahlert, 1902). The 
existence of the intermediate has never been found to date. Many review articles on arynes 
prior to the year 2000 have been published (Wittig, 1957, 1965; Burnett, 1961; Heany, 1962; 
Hoffman, 1967; Fields and Meyerson, 1969; Kessar, 1978) and heteroarynes (Kauffman, 
1965; Den Hertog and Van der Plas, 1965, 1969; Kauffman and Wirthwein, 1971; Reinecke, 
1982; Sander, 1999) as well as the years after (vide infra) which bespeaks of their relevance 
and importance in chemistry. 
 
Figure 1.3: The first proposed heteroaryne. 
These reactive species have emerged as versatile and effective tools in organic 
synthesis for the construction of complex natural products of biological importance and for 
the design and development of novel architecturally unique scaffolds for drug discovery 
(Gampe and Carreira, 2012; Tadross and Stoltz, 2012; Goetz, Shah et al., 2015).  According 
to Stoltz, by 2012, more than 75 individual natural products had been synthesized or prepared 
  3 
using arynes to generate key synthetic intermediates (Tadross and Stoltz, 2012) which 
demonstrates their usefulness in organic syntheses. Figure 1.4 shows examples of hetarynes 
that have been reported in the literature: 2,3-pyridyne, 1.16 (Martens and den Hertog, 1962); 
3,4-pyridyne, 1.17 (Kauffman and Boettcher, 1961); 2,3-thiophyne (Reinecke, Newsom et 
al., 1981); 1.18, 3,4-thiophyne, 1.19 (Reinecke, Newsom et al., 1981), 1-Boc-3,4-pyryne, 
1.20 (Liu, Chan et al., 1999); 2,3-quinolyne, 1.21 (Fleet and Fleming, 1969); 3,4-quinolyne, 
1.22 and 5,6-quinolyne, 1.23 (Kauffman and Fischer, 1967); 7,8-quinolyne, 1.24 (Collis and 
Burrell, 2005); 1,2-didehydrobenzothiophene, 1.25 (Reinecke, Newsom et al., 1981); 4,5-
indolyne, 1.26, 5,6-indolyne, 1.27 and 6,7-indolyne, 1.28 (Buszek, Brown et al., 2007); 4,5-
didehydrobenzofuran, 1.29, 5,6-didehydrobenzofuran, 1.30, 6,7-didehydrobenzofuran, 1.31 
(Brown and Buszek, 2012); 1,2-carbazolyne, 1.32 (Brown, Choi et al., 1997) and 3,4-
carbazolyne, 1.33 (Goetz, Silberstein et al., 2014). 
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Figure 1.4: Arynes and hetarynes shown in their common triple bond canonical 
representation. 
 
Arynes and hetarynes have been extensively used in the total synthesis of several 
important natural products as shown in figure 1.5. Among the recent examples, the powerful 
synthetic utility of benzyne was demonstrated by Stoltz in the total synthesis of the 
tetrahydroisoquinoline alkaloid, (-)-quinocarcin, 1.35 (Allan and Stoltz, 2008) and more 
recently in the synthesis of (-)-curvularin, 1.36, a naturally occurring benzannulated 
macrolactone (Tadross, Virgil et al., 2010). The 3,4-pyridynes have proved to be strategic in 
the concise syntheses of naturally occurring alkaloids such as (s)-macrostomine, 1.37 
(Enamorado, Ondachi et al., 2010) and ellipticine, 1.38 (Diaz, Cobas et al., 2001). Most 
recently, the advantages of 6,7-indole aryne chemistry in particular have been successfully 
exploited by the Buszek laboratories to access rapidly the trikentrins (1.39-1.40) and the 
herbindoles (1.41-1.42). Also, there are reports of the 4,5-indole aryne being utilized as an 
intermediate in the total syntheses of the members of the welwitindolinone family of natural 
products such as N-methylwelwitindolinone C isothiocyanate, 1.43 (Huters, Quasdorf et al., 
2011), N-methylwelwitindolinone D isonitrile, 1.44 (Styduhar, Huters et al., 2013) and (-)-N-
methylwewitindolinone B isothiocyanate, 1.45 (Weires, Styduhar et al., 2014). The 
construction of a carbazole-containing alkaloid, (+)-tubingensin A, 1.46 was carried out by 
efficiently employing the carbazolyne cyclization strategy (Goetz, Silberstein et al., 2014).  
  5 
 
Figure 1.5: Examples of natural products that used the aryne and hetaryne methodologies in 
their total synthesis.  
 
Significantly, the Buszek laboratories strategically utilized the 6,7-indole aryne 
chemistry for the first example of small molecule library synthesis, namely, an 
unprecedented 93-member library of polycyclic, benzannulated indoles of biological 
relevance (Thornton, Brown et al., 2011). The 6,7-indole aryne generated from the 4,6,7-
tribromoindole precursor via a regioselective metal-halogen exchange and elimination 
protocol (Buszek, Luo et al., 2007), was trapped with diene partners such as furan and 
cyclopentadiene to achieve annulation at the 6,7-position of the indole nucleus. The 
cycloadduct olefin was reduced by diimide prior to subjecting the remaining 4-bromo 
positions to a series of cross-coupling reactions such as Suzuki-Miyaura and Buchwald-
  6 
Hartwig to introduce various adornments at the 4-position, thus enabling the development of 
structurally diverse library members. 
 
Scheme 1.2: Examples of diverse library construction using a 6,7-indole aryne cycloaddition 
and cross-coupling tactic. 
 
Notably, the newly synthesized benzannulated indole scaffolds exhibited anti-
proliferative activities at micromolar and sub-micromolar concentrations in the L1210 
leukemia and HL-60 promyelocytic leukemia cell based assays (Perchellet, Waters et al., 
2012). The proposed mechanism of action of these library members in L1210 leukemia cell 
lines was apoptotic DNA degradation and nuclear fragmentation. Furthermore, in a 
subsequent HL-60 cell based study discussed in detail in chapter 4, these compounds 
inhibited the proliferation of tumor cells through microtubule de-stabilization, a mode of 
action that resembles that of an established anti-cancer drug, vincristine (Perchellet, J., 
Perchellet, E et al., 2014). The compelling biological results obtained in the cell-based assays 
helped to validate the significance of 6,7-indole aryne chemistry in library development and 
drug discovery. 
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CHAPTER 2 
THERAPEUTICS INSPIRED BY NATURAL PRODUCTS 
2.1: Benzannulated Indole Alkaloid Natural Products as Inspiration for Library 
Development and Syntheses 
 
Natural products from various sources have demonstrated unparalleled importance in 
drug discovery, most of which is well documented in a number of articles (Chabala, 1998; 
Jack, 1998; Gurib-Fakim, 2006; Weissman and Muller, 2009; Dias, Urban et al., 2012; 
Sucher, 2013). Drug discovery from medicinal plants have led to the isolation of drugs with 
structural and biological targets diversity (Figure 1). Some of the representative members of 
these medicinally derived pharmaceuticals include: reserpine (antihypertensive agent, 
isolated from Rauwolfia serpentine), ephedrine and later salbutamol and salmeterol (anti-
asthma agents (beta agonists) isolated from Ephedra sinica), tubocurarine (muscle relaxant, 
isolated from Chondrodendron and Curarea species), taxol (anticancer, isolated from the 
stem bark of the western yew, Taxus breuifolia), vinca alkaloids: vinblastine and vincristine 
(anticancer, isolated from the Madagascar periwinkle, Catharanthus roseus), cocaine 
(stimulant, isolated from the coca leaves, Erythroxylum coca), morphine (centrally acting 
analgesic, isolated from the opium poppy Papaver somniferum), digitoxin (cardiotonic, from 
digitalis), aspirin (analgesic, isolated from the bark of the willow tree or the Salix species) 
and quinine (antimalarial, from the bark of Cinchona  officinalis) (Chabala, 1998; Jack, 1998; 
Gurib-Fakim, 2006; Weissman and Muller, 2009; Dias, Urban et al., 2012; Sucher, 2013). 
These medicinally derived drugs have augmented the lives of many people as evidenced in 
humankind reliance of these drugs up to date. 
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Figure 2.1: Therapeutic drugs from medicinal plants	  
Other than medicinal plants, natural products drug discovery has also traditionally 
focused on environmental pharmacopeia like forests, soils and lakes. These sources have 
resulted in powerful antibiotic drugs such as penicillin, isolated from the filamentous fungus 
Penicillium notatum) (Cragg and Newman, 2001), cephalosporins, tetracyclines, 
aminoglycosides, rifamycins, chloramphenicol, and lipopeptides among others 
(Schwartsmann, 2000; Jeffreys, 2004; Butler, 2005; Beutler, 2009; Mishra and Tiwari, 2011). 
However, marine environment sources: sponges (phylum: Porifera), corals, mollusks, 
ascidians, bryozoans and more recently bacterial strains that live in association with these 
organisms have also proved to be a rich source drug like substances. These compounds 
portray structural molecular diversity and unique biological targets, hence they have 
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consequently inspired drug development to yield therapeutically useful drugs such as: 
eribulin/Haloven; anticancer drug from halicondrin B (isolated from Axinella sp., Phakellia 
carteri Lissondendryx sp. and Halichondria okadai sp.), pseudopterosins; antiinflamatory 
drug isolated from the gorgonian coral Pseudopterogorgia elisabethae), trabectedin 
(Yondelis); anticancer drug whose active substance is a natural product ecteinascidin 743 
which was originally isolated from the Caribbean sea squirt, Ecteinascidia turbinate and 
Brentuximab vedotin (Adcetris); the latest marine anticancer drug to successfully enter into 
the market, is based on a synthetic analog of dolastatin 10 isolated from the sea hare 
Dolabella auricularia (Martins, Viera et al., 2014). 
Peculiarly, most of these natural products from medicinal plants, marine sources and 
other natural sources portray high structural chemical diversity, biochemical specificity, 
binding efficiency and propensity to interact with biological targets, which make them 
successful pharmaceutical drugs. In fact, half of the best-selling pharmaceuticals by 1991 
were actually based on a natural product precursor or pharmacophore (Cordell, 2000) and in 
both 2001 and 2002, approximately one quarter of the bestselling drugs worldwide were 
natural products or derived from natural products (Balunas and Kinghorn, 2005). 
 
  10 
 
Figure 2.2: Marine derived Pharmaceuticals 
In drug design and library development, many structural features common to natural 
products (e.g., stereogenic centers, aromatic rings, complex ring systems, degree of molecule 
saturation, and number and ratio of heteroatoms) have been shown to be highly relevant to 
drug discovery efforts (Balunas and Kinghorn, 2005). It is also noted that from a discovery 
perspective, the key concept in developing a library is to maximize the chemical diversity. 
These programs consider the key scaffold component in medicinal chemistry as the ring 
systems, which are the fundamental building blocks of most drugs on the market today. The 
  11 
importance of rings and their significant role in molecular properties such as the electronic 
distribution, three dimensionality, and scaffold rigidity is well understood (Taylor, MacCoss 
et al., 2014). According to Taylor, rings are often key factors in whole molecule properties 
such as lipophilicity or polarity and can determine molecular reactivity, metabolic stability, 
toxicity and overall novelty of a molecular library.  
Coincidentally, combinatorial chemistry has emerged as a powerful tool in library 
development due to its utilization to prepare a large number of different compounds from a 
single scaffold or backbone. Majority of medicinal synthetic efforts in drug discovery are 
known to target diverse molecular skeletons than the appendices for high-throughput 
screening. The rationale is that this approach in compound libraries is found to achieve a high 
degree of skeletal diversity, and thereby effectively increasing the chances of compounds 
occupying unpopulated regions of the chemical property space and consequently, the hit rates 
for diverse biological targets in “biological space” (Zhang, Zheng et al., 2014). It is therefore 
prudent to design and synthesize libraries that combine the structural features of natural 
products with the compound-generating potential of combinatorial chemistry (Hall, Manku et 
al., 2001; Eldridge, Vervoot et al., 2002; Burke, Berger et al., 2004; Ganesan, 2004; Tan, 
2004).  
Towards these efforts, Buszek laboratory recently constructed unprecedented 163- 
and 43-member lactam libraries (Scheme 2.2) based on the eight-membered ring motif 
(Brown, Gao et al., 2008) via ring-closing metathesis (RCM) and inspired by the potent 
antitumor marine polyketide octalactin A (Figure 2.3) (Buszek, Sato et al., 1994). The 
skeletal structure of octalactin A features a rare saturated eight-membered lactone core.  
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Figure 2.3: Octalactin A 
Medium ring natural products are uncommon and there is a widely held view that 
medium rings are the most challenging and difficult systems to synthesize (Illuminati and 
Mandolini, 1981). The basic scaffold was readily constructed in a convergent fashion with 
the major sources of diversity being commercially available protected L -amino acids, 
benzaldehydes, and benzyl amines and lactonization via facile Grubb’s first or second 
generation catalyst’s ring-closing metathesis. Derivatization of the amine R2N was achieved 
by use of functional groups most likely to be found in pharmacophores, namely; tertiary 
amines, amides, sulfonamides, carbamates, and ureas. The resultant library was a novel 163-
member eight-membered lactam demonstration library, the first based on a monocyclic 
medium-ring platform (Scheme 1) (Brown, Gao et al., 2008). 
 
Scheme 2.1: 163-member 8-membered ring lactam library 
In preliminary anti-proliferative biological screens with murine L1210 lymphocytic 
leukemia, human HL-60 promyelocytic leukemia, and murine Pan02 pancreatic ductal 
adenocarcinoma cell lines, some of these library members exhibited low micromolar to sub-
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micromolar inhibition in these assays. Moreover, pilot-scale libraries of these eight-
membered medium ring lactams (MRLs) and related tricyclic compounds were screened for 
their ability to inhibit the catalytic activity of human recombinant 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase in vitro. A dozen of these synthetic 
compounds mimicked the inhibition of purified HMG-CoA reductase activity caused by 
pravastatin, fluvastatin and sodium salts of lovastatin, mevastatin and simvastatin in the 
studied cell-free assay, suggesting direct interaction with the rate limiting enzyme of 
cholesterol biosynthesis. Moreover, several MRLs inhibited the metabolic activity of L1210 
tumor cells in vitro to a greater degree than fluvastatin, lovastatin, mevastatin and 
simvastatin, whereas pravastatin was found to be inactive (Perchellet, J., Perchellet, E et al., 
2009). 
Similarly, the design and synthesis of interesting scaffolds that are based on either 
unknown or highly underrepresented chemotypes (unique chemical entity) in the National 
Institutes of Health PubChem database and Molecular Libraries Small Molecule Repository 
(MLSMR), remains an important strategy for library development and drug discovery 
(Suggitt and Bibby, 2005). Annulated indoles at the benzene ring are highly underrepresented 
in chemical property space by comparison to structures in the PubChem database and the 
National Institutes of Health Molecular Libraries Small Molecule Repository (MLSMR). By 
contrast, annulated indoles at the pyrrole ring (2,3-pyrrole annulation, Figure 2.4) are 
ubiquitous in nature and well represented in the aforementioned databases. Annulation is 
described as the fusion or attachment of a ring in a cyclic system as depicted in the indole 
nucleus (Figure 2.4).  
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Figure 2.4: Annulation pattern examples on the indole nucleus. 
A few biologically active benzannulated compounds in this underrepresented class 
include the trikentrins, herbindoles, teleocidins, nodulisporic acids, stephacidins and 
notoamides (Chapter 3). Recently, we built the first 93-member library of polycyclic 
benzannulated indoles3.4 inspired by the trikentrin and herbindole family of alkaloid natural 
products (Brown, Luo et al., 2009; Buszek, Brown et al., 2009; Chandrasoma, Brown et al., 
2013) using our indole aryne [4+2] cycloaddition methodology (Scheme 1). The biological 
results, detailed in chapter 4 concluded that several of these annulated indoles mimicked the 
effect of vincristine, but not that of taxol, on tubulin polymerization and therefore these 
compounds might represent a new class of microtubule de-stabilizing agents that inhibit 
tubulin polymerization (Perchellet, Waters et al., 2012).  
Other members of these annulated indole libraries remarkably increased the rate and 
level of actin polymerization in a manner similar to jasplakinolide, suggesting that they might 
also stabilize the cleavage furrow to block cytokinesis. Finally, these indoles appeared to 
interact with both tubulin to decrease microtubule assembly and actin to block cytokinesis, 
thereby inducing bi- and multi-nucleation resulting in genomic instability and apoptosis. 
Collectively, these compelling biological results clearly helped to validate the significance of 
these unprecedented scaffolds. 
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CHAPTER 3 
BENZANNULATED INDOLE ALKALOID NATURAL PRODUCTS DISCOVERY, 
ISOLATION AND SYNTHESES  
A few natural products exhibit the rare benzannulation. These bioactive natural products will 
be discussed in this chapter.  
3.1: Trikentrins 
The two most common members of the benzene annulated indole alkaloid natural 
products are the trikentrins (Figure 3.1) (Capon, Macleod et al., 1986), and the herbindoles 
(Figure 3.2) (Herb, Carroll et al., 1990). In 1986 Capon and co-workers isolated five new 
benzannulated indole alkaloids namely, (+)-cis-trikentrin A, (+)-cis-trikentrin B, (+)-trans-
trikentrin A, (-)-trans-trikentrin B and iso-trans-trikentrin B, from the marine sponge 
Trikentrion flabelliforme, collected off of the Australian coast in Darwin (Capon, Macleod et 
al., 1986). These compounds exhibit growth inhibitory activity toward gram-positive 
bacteria, Bacillus subtilis, (Capon, Macleod et al., 1986) but no activity levels were provided. 
This family of indole alkaloids show exclusive cyclopentenoid annulation at the 6,7-position 
of the benzene side of the indole nucleus with either cis- or trans-1,3-dimethyl groups and an 
additional carbogenic substituent at either the 4- or 5-position as shown below. 
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Figure 3.1: Benzannulated indole alkaloids: trikentrins 
3.2: Herbindoles 
In 1990 Scheuer and co-workers isolated three new structurally related benzannulated 
indole alkaloids from the Australian sponge Axinella sp. (Herb, Carroll et al., 1990). These 
compounds were named herbindole A, herbindole B and herbindole C. These compounds 
exhibited cytotoxicity against KB cells as well as fish antifeedant properties (Herb, Carroll et 
al., 1990). 
 
Figure 3.2: Benzannulated indole alkaloids: herbindoles 
 
Although the biosynthesis of trikentrins and herbindoles are unknown, they are 
apparently not derived biogenetically from tryptophan as they lack substitution at C3 
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position.  Trikentrins and herbindoles are deceptively simple but synthetically challenging 
molecules.  
3.3: Teleocidins 
The Teleocidin B family of compounds (Figure 3.3) first isolated from Streptomyces 
mediocidicus (Awakawa, Zhang et al., 2014) and also produced by actinomycetes 
(Takashima, Sakai et al., 1962). This class of alkaloids consists of four stereoisomers which 
are interesting indole alkaloids primarily because of their uncommon 6,7 cyclohexanoid 
benzannulation featuring a 9-membered indolactam bridging the indole 3- and 4-positions. 
The 6,7-annulation is also endowed with two non-adjacent quaternary centers. In the same 
family, teleocidin A is structurally similar to teleocidin B as they both share the 9-membered 
lactam but lacks the 6,7-benzannulation. Instead, teleocidin A has a C7 tether with a 
stereogenic center that differs in teleocidin A1 and A2 (Xu, Zhang et al., 2011). Teleocidins 
exhibit tumor-promoting activity, which involves binding and activating a group of kinase 
receptors including protein kinase C (Xu, Zhang et al., 2011). 
 
Figure 3.3: Teleocidin B family. 
The immense synthetic challenges associated with the benzannulation in teleocidin B 
family are evidenced by the fact that there is no total synthesis of the teleocidin B family 
reported to date. This is further substantiated by fact that the total synthesis of a structurally 
similar indolactam V which lacks the 6,7-hetero-benzannulation (Xu, Zhang et al., 2011).  
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3.4: Notoamides  
Other structurally similar members of these uncommon benzannulated isoprenylated 
indole alkaloids are the antifungal notoamides (Figure 3.4) and the antitumor stephacidins 
(Figure 3.5) isolated from Aspergillus ochraceus (Kato, Yoshida et al., 2007; Greshock, 
Grubbs et al., 2007; (Tsukamoto, Kato et al., 2008; J. Nat. Prod. 2008; Tsukamoto, Kato et 
al., 2009). These compounds exhibit a heteronuclear annulation at the 6,7-position of the 
indole nucleus as well as pyrrole annulation in notoamide D.  Notoamides are secondary 
metabolites produced by the marine-derived Aspergillus species, which was isolated from the 
mussle, Mytilus edulis galloprovincialis, collected off the Noto Peninsula in the Sea of Japan 
(Kato, Nakamura et al., 2011).  
 
Figure 3.4: Representative members of notoamides. 
3.5: Stephacidins 
Stephacidins are isolated from Aspergillus ochraceus.	  This family is biosynthetically 
derived from tryptophan, a cyclic amino acid, and either one or two isoprene units. These 
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alkaloids show diverse bioactivities, including antitumor, insecticidal, and calmodulin 
inhibition (Cai, Luan et al., 2013; Finefield, Kato et al., 2011). 
 
Figure 3.5: Representative members of stephacidin family. 
3.6: Penitrems 
Contrary to 6,7 annulation as shown in notoamides, herbindoles, trikentrins and 
teleocidins, penitrems (Figure 3.6) feature a 4,5-annulation on the benzenoid as well as 
pyrrole ring annulation (Wilson, B, Wilson C et al., 1968; Smith, Kuerti et al., 2007).  
Additionally, they exhibit a cyclobutane moiety, an eight-membered cyclic ether ring 
connection between the cyclobutane ring and the secondary cyclopentanol on the pyrrole 
ring. Penitrems are indole-diterpene tremogens produced by ergot fungi that grow on a 
variety of grasses endemic to South Africa, New Zealand and the United States (Smith, 
Kanoh et al., 2000). 
 
Figure 3.6: The family of penitrems. 
3.7: Nodulisporic Acids 
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This family of benzannulated indole alkaloids also feature both benzenoid and pyrrole 
annulation. This class of alkaloids features annulation at the 5,6-position of the benzene ring 
as well as 2,3-pyrrole annulation. Some members of this family, specifically nodulisporic 
acid A and B exhibit an additional ring connection to nitrogen of the pyrrole ring with the C7 
position of the benzene ring. 
Nodulisporic acids (Figure 3.7) are a family of potent indole alkaloid that shows 
potent anti-parasitic activity and were isolated by Ondeyka and co-workers at the Merck 
Research Laboratories (Ondeyka, Helms et al., 1997; Ondeyka, Dahl-Roshak et al., 2002; 
Ondeyka, Byrne et al., 2003; Singh, Ondeyka et al., 2004). Isolation of (+)-nodulisporic acid 
A which is the most complex member of the nodulisporane class of indole diterpenoids 
(Ondeyka, Helms et al., 1997) was reported and found to be particularly effective against flea 
and tick infestations in companion animals (Sings and Singh, 2003). Further in vitro and in 
vivo evaluation against the bedbug Cimex lectularius also revealed (+)-nodulisporic acid A to 
display a 10-fold greater systemic adulticidal efficacy (LD90 =1 ppm) over the currently 
prescribed flea insecticide ivermectin (LD90 = 10 ppm) (Smith, Davulcu et al., 2007). On 
close inspection and of particular interest to our group, other members of the nodulisporic 
acid family proved to be 5- to >100-fold less active (Smith, Davulcu et al., 2007). Among 
other differences, one of the major glaring difference in nodulisporic acid A and others was 
the C7 to indole N ring connection (D ring) which may signify the importance of this ring 
towards its biological activity. We were interested in constructing indole containing 
structures that feature this unique ring connection motif as shown in Nodulisporic acid A. 
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Figure 3.7: Representative members of nodulisporic acid class. 
Importantly, (+)-nodulisporic acid A revealed no apparent toxicity to the host animal, 
while effectively killing the fleas subsequent to their ingestion of a blood meal. The lack of 
mammalian toxicity is ascribed to the observation that (+)-nodulisporic acid A is active only 
against glutamate-gated ion channels that are specific to invertebrates and not against 
glycine- and GABA-gated chloride ion channels common in mammals (Smith, Davulcu et 
al., 2007). It was determined that Nodulisporic acid A exerts its striking insecticidal activity 
by selectively modulating an invertebrate specific glutamate-gated chloride ion channel for 
which no mammalian homologue exists (Smith, Warren et al., 2000). As a result, (+)-
nodulisporic acid A is capable of selectively killing insects, while having no adverse effect 
on mammals.  
In synthetic efforts of the nodulisporic acids A and B, the aforementioned highly 
strained D ring was installed by a late-stage Hendrickson annulation tactic albeit enormous 
difficulties (Smith, Kuerti et al., 2007). 
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CHAPTER 4 
BIOLOGICAL STUDIES AND RESULTS FROM A BENZANNULATED  
            INDOLE SCAFFOLDS LIBRARIES 
4.1: Synthesis of the benzannulated cross-coupled indole library 
In continuous efforts towards drug discovery, design and library development in the 
Buszek group, the first 93-member benzannulated indole library inspired by the trikentrin 
and herbindole family of alkaloid natural products was synthesized using the group’s 
discovery of the indole aryne generation methodology (Buszek, Brown et al., 2007) followed 
by cycloaddition and cross-coupling chemistry as demonstrated in the scheme below (Brown, 
Buszek et al., 2009). 
 
Scheme 4.1: Benzannulated and cross-coupled indole libraries. 
The key scaffold: 4,6,7-tribromoindole scaffold was synthesized using the Bartoli 
indole synthesis reaction (Bartoli, Palmieri et al., 1989; Bartoli, Bosco et al., 1991; Bosco, 
Dalpozzo et al., 1991; Dalpozzo and Bartoli, 2005) and follows the group’s previously 
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published route (Scheme 2) (Brown, Luo et al., 2009). Synthetic efforts started with a 
commercially available o-nitroaniline 3.1, which was first brominated at C2 and C4 (HBr, 
MeOH/CH2Cl2, 90%), followed by diazotization to afford the 2,3,5-tribromonitrobenzene. 
Application of the Bartoli reaction conditions (vinylmagnesium bromide, 6.0 equiv, 
tetrahydrofuran (THF), -40 oC) consistently gave the desired indole in 45% yield on up to 
more than 50 g scale. 
	  
Scheme 4.2: Bartoli Indole Synthesis 
  The indole nitrogen was alkylated with methyl iodide (88%) to afford the desired N -
methyl indole scaffold 1.47. Indole aryne generation was achieved by our Buszek’s group 
optimized conditions (n-BuLi, 1.2 equiv, toluene, -78, oC to rt) followed by cycloaddition 
with either cyclopentadiene or furan that gave the corresponding cycloadducts in 72% and 
84% yields, respectively. Olefin reduction was achieved via diimide (generated in situ from 
o-nitrobenzosulfonhydrazide, 1.51 and tri-ethylamine) as the presence of the alkene resulted 
in sharply diminished yields in the subsequent cross-coupling reactions (Buszek and Brown, 
2007). The resulting scaffolds with the bridged bicyclic system represented an uncommon 
structural motif in library design. A correlation study had suggested that presence of 
additional sp3 -hybridized content in complex library structures increased the number of hits 
  24 
for activity in certain cell-based assays, particularly in the area of CNS (e.g., histone 
deacetylase, or HDAC, inhibition) (Marcaurelle, Comer et al., 2010)  
 
Scheme 4.3: Metal-halogen exchange/elimination and cycloaddition with cyclopentadiene or 
furan followed by diimide reduction  
 
The key scaffolds were then subjected to Suzuki-Miyaura and Buchwald-Hartwig 
reactions cross-coupling conditions resulting in a 93-member library reminiscent of 
structures as shown in scheme 4.1. The annulated library comprised of 51-member 
Buchwald–Hartwig cross-coupled sub-library and 42-member Suzuki–Miyaura sub-library. 
In silico profiling (Lipinski, Lombardo et al., 1997; Pearlman, Smith et al., 1999; Cruciani, 
Meniconi et al., 2003) of physicochemical and ADME properties, suggested that the 6,7-
indole aryne products generated from these libraries should be reasonably amenable to both 
biochemical and cell based assays and meant that the libraries were fully compliant with the 
Lipinski Rule of Five (Lipinski, Lombardo et al., 1997) in that none of the constituent 
compounds had more than one violation, and nearly two-thirds of the species had no 
violations.  
 The full product manifold showed a wide range of chemical diversity, specifically 46 
distinct cells in chemical space, which reflected a significant amount of chemical diversity in 
these library elaborations. One of the desired traits of molecular library members is to occupy 
unpopulated or sparsely populated chemical property space, which usually translates to these 
molecular entities demonstrating new modes/mechanisms of action in their molecular targets. 
These compounds were then submitted to the NIH Molecular Libraries Screening Centers 
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Network (MLSCN) for biological evaluation with a broad range of biochemical and cell 
based assays and the resulting compelling biological results obtained from these various 
efforts helped to validate the significance of these libraries using benzannulated indole 
scaffolds as privileged structures in drug design and development. 
From the 93-member library, a subset of 66 novel 6,7-annulated-4-substituted indole 
compounds were tested for their effectiveness against murine L1210 tumor cell proliferation 
in vitro. Most compounds inhibited the metabolic activity of L1210 lymphocytic leukemia 
cells in a time- and concentration dependent manner and nine of them, arbitrarily chosen 
between 0.5 to 4 micro-molar inhibitions (Figure 4.1) were sufficiently potent to inhibit 
L1210 tumor cell proliferation by 50%. Interestingly, all nine compounds with the exception 
of one came from the Buchwald-Hartwig secondary amine cross-coupled compounds. The 
lone Suzuki – Miyaura cross- coupled bioactive compound was also found to be the weaker 
anti-proliferative compound in the HL-60 cell assay. However, all nine Antiproliferative 
compounds induced DNA cleavage at 24 h in L1210 cells that contained 3H-thymidine pre-
labeled DNA, suggesting that these antitumor-annulated indoles might trigger an apoptotic 
pathway of DNA fragmentation. 
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Figure 4.1: L1210 lymphocytic leukemia cells active compounds 
 
In another subsequent study, six of the nine synthetic 6,7-annulated-4-substituted 
indole compounds reported to have interesting antitumor effects in the L1210 tumor cell 
system (Perchellet, Waters et al., 2012) were selected for the study with human HL-60 pro-
myelocytic leukemia cells (Figure 4.2). These six compounds were selected for the HL-60 
study because they had the best anti-proliferative IC50 values in L1210 cells at day 2 in 
relation with their ability to inhibit DNA synthesis at 3 h and induce DNA fragmentation at 
24 h. This suggested that these annulated indoles were the most effective in short-term 
antitumor assays and might have a more rapid mechanism of action, needing less time to 
interact with and be incorporated into cells, undergoing eventual metabolic activation to 
reach crucial cellular targets, and trigger various inhibitory pathways that finally damage and 
kill tumor cells (Perchellet, Waters et al., 2012).  
These synthetic 6,7-annulated-4-substituted indole compounds, were tested for their 
ability to inhibit human HL-60 tumor cell proliferation, disrupt mitosis and cytokinesis, and 
interfere with tubulin and actin polymerization in vitro. The concentration-dependent 
inhibition of HL-60 tumor cell proliferation by the annulated indoles was found to be always 
more pronounced at day four rather than day two, suggesting that the efficacy of these 
bioactive compounds was a combination of their concentration and duration of action.  
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Figure 4.2: Benzannulated indole compounds tested against human HL60 tumor cell line 
 
The ability of annulated indoles to alter the polymerizations of purified tubulin and 
actin were monitored in cell-free assays and were compared to the effects of drugs known to 
disrupt the dynamic structures of the mitotic spindle and cleavage furrow: jasplakinolide 
(JAS), taxol and vincristine (VCR). Jasplakinolide is a potent inducer of actin polymerization 
and stabilization that interferes with actomyosin ring function and impedes cytokinesis. 
Vincristine and taxol are known microtubule (MT) disrupting agents; where VCR blocks 
tubulin polymerization and MT assembly, and taxol lower the critical concentration (CC) of 
free tubulin required to promote polymerization and blocks MT disassembly.  
These annulated indoles inhibited the metabolic activity of HL-60 tumor cells in the 
low-micromolar range in culture. However, when tested as positive controls in the same 
experiments, established anticancer drugs like daunorubicin and jasplakinolide (JAS), a cell-
permeable F-actin probe with fungicidal, insecticidal and antitumor properties, inhibited the 
growth of HL-60 tumor cells at much lower nanomolar concentrations as illustrated in figure 
4.3. 
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Reproduced with permission from [Anticancer Res 2014, 34, 1643] 
 
Figure 4.3: Comparison of the ability of serial concentrations (logarithmic intervals) of KU-
70, KU-72 and KU-80 to inhibit the metabolic activity of HL-60 tumor cells at days 2 (open 
symbols) and 4 (solid symbols) in vitro. The antiproliferative activities of jasplakinolide 
(JAS) concentrations at days 2 and 4 are indicated for the sake of comparison. HL-60 cell 
proliferation results are expressed as percentage of the net absorbance of MTS/formazan 
after bioreduction by vehicle-treated control cells after two (A490 nm=1.179±0.048) and 
four (A490 nm=1.149±0.047) days in culture (100±4.1%, striped area). The blank values 
(A490 nm=0.370 at day 2 and 0.439 at day 4) for cell-free culture medium supplemented 
with MTS:PMS reagent were subtracted from the results. Data are means±SD (n=3). a Not 
different from respective controls; bp<0.05, cp<0.025 and dp<0.01, significantly lower than 
respective controls. 
 
Antiproliferative concentrations of annulated indoles were also found to increase the 
mitotic index of HL-60 cells similarly to vincristine (Figure 4.4) and stimulated the formation 
of many non-viable cells: bi-nucleated cells, multi-nucleated cells and micronuclei (Figure 
4.5), similarly to taxol and jasplakinolide. This suggested that these antitumor compounds 
might increase mitotic abnormality, induce chromosomal damage or missegregation, and 
block cytokinesis. Since annulated indoles mimicked the effect of vincristine on tubulin 
polymerization, but not that of taxol, these compounds represented a new class of 
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microtubule de-stabilizing agents that inhibit tubulin polymerization. Moreover, annulated 
indoles remarkably increased the rate and level of actin polymerization similarly to 
jasplakinolide, suggesting that they might also stabilize the cleavage furrow to block 
cytokinesis.  
                
Reproduced with permission from [Anticancer Res 2014, 34, 1643] 
 
Figure 4.4: (Left). Comparison of the effects of KU-70 (10 µM), KU-72 (10 µM), KU-80 (10 
µM), vincristine (VCR, 0.05 µM), taxol (0.05 µM) and jasplakinolide (JAS, 0.32 µM) on the 
frequency of mitotic figures (A) and bi-nucleated cells (B) in HL-60 tumor cells in vitro. HL-
60 cells were incubated in triplicate for 24 (open columns) and 48 h (closed columns) at 
37˚C in the presence or absence (C: control) of the indicated drugs. The percentage of cells 
in each category was determined by morphological analysis, scoring an average of 
approximately 5,000 cells/slide to identify those containing mitotic figures or two nuclei. 
Results are expressed as the percentage of mitotic (A) or bi-nucleated cells (B) in drug-
treated cultures relative to the mitotic (C: 1.34±0.12%) or binucleated (C: 2.66±0.23%) cells 
in vehicle-treated controls. Data are means±SD (n=3). aNot different from control; 
bp<0.005 and cp<0.0005, significantly smaller than respective controls in A and B; 
dp<0.025, ep<0.005 and fp<0.0005, significantly greater than respective controls in A and 
B. 
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Figure 4.5 (Right). Comparison of the effects of KU-70 (10 µM), KU-72 (10 µM), KU-80 (10 
µM), vincristine (VCR, 0.05 µM), taxol (0.05 µM) and jasplakinolide (JAS, 0.32 µM) on the 
frequency of multi-nucleated cells (A) and micronuclei (B) in HL-60 tumor cells in vitro. HL-
60 cells were incubated in triplicate for 24 (open columns) and 48 h (closed columns) at 
37˚C in the presence or absence (C: control) of the indicated drugs. The percentage of cells 
in each category was determined by morphological analysis, scoring an average of about 
5,000 cells/slide to identify those containing 3-4 nuclei or MNi. A: Results are expressed as 
the percentage of multi-nucleated cells in drug-treated cultures relative to the multi-
nucleated cells (C: 0.54±0.04%) in vehicle-treated controls. B: Results are expressed as the 
percentage of vehicle- (C: 0.04±0.002%) or drug-treated cells with MNi. Data are 
means±SD (n=3). ap<0.0005, significantly smaller than control; bNot different from 
respective controls in A and B; cp<0.025, and dp<0.0005, significantly greater than 
respective controls in A and B. 
 
Glycerol and taxol stabilize tubulin and lower the critical concentration of protein 
required to initiate microtubule assembly (Engelborghs, 1990; Perchellet J., Perchellet E et 
al., 2014). The effects of anti-proliferative annulated indoles on tubulin polymerization in the 
presence or absence of glycerol was studied and the control curve shown in Figure 4.6 
indicated a concentration of purified tubulin below 10 mg/ml which could not polymerize in 
the absence of 15% glycerol. However, the MT stabilizing drug taxol can easily induce the 
polymerization of such a low concentration of tubulin (1.15 mg/ml) in the absence of 15% 
glycerol. However, up to 300 µM KU-72 was not able to promote tubulin polymerization in 
the absence of glycerol indicating that KU-72 is not a MT-stabilizing agent but acts by 
blocking MT disassembly like taxol.  
The control curves in Figure 4.6 shows the three typical phases of MT assembly 
taking place when purified tubulin (2.25 mg/ml) undergoes polymerization in the presence of 
15% glycerol: a short lag phase, an exponential growth phase almost linear between 100 and 
400 s, and a steady phase reaching a plateau after 520 s (Perchellet J., Perchellet E et al., 
2014). At 10 µM, compared to the control, VCR almost totally inhibited the rate and extent 
of glycerol-induced tubulin polymerization by 94.5% and 93.7%, respectively (Figure 4.6B). 
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At 300 µM, KU-72 mimics the inhibitory effect of VCR and reduces the rate and extent of 
glycerol-induced tubulin polymerization by 72.2% and 70.5%, respectively, suggesting that 
this annulated indole, which increased the mitotic cell index like VCR (Figure 4.4A), might 
also be a MT de-stabilizing drug that prevents MT assembly (Figure 4.6B).  
 
Reproduced with permission from [Anticancer Res 2014, 34, 1643] 
Figure 4.5: Comparison of the ability of antiproliferative KU-72 and known microtubule 
(MT)-stabilizing (A) and MT de-stabilizing (B) anticancer drugs to respectively alter the 
kinetics of tubulin polymerization in the absence (A) or presence (B) of glycerol in vitro. A: 
Purified tubulin was diluted to a final concentration of 1.15 mg/ml in 80 mM PIPES buffer, 
pH 6.9, containing 10 mM MgCl2, 1 mM EGTA and 1 mM GTP. The polymerization 
reactions were placed in quartz microcells and incubated at 35˚C in the presence or absence 
(control) of 300 µM KU-72 or 10 µM taxol. B: The turbidity assay mixtures were identical to 
those of (A) but contained 2.25 mg tubulin/ml and 15% glycerol. The polymerization 
reactions were similarly incubated in the presence or absence (control) of 300 µM KU-72 or 
10 µM vincristine (VCR). The rate of MT assembly was continuously monitored by scanning 
over 900 s the increase in turbidity (absorbance at 340 nm). Assays were performed in 
duplicate. 
 
Glycerol-induced tubulin polymerization between 80 and 520 s is inhibited by 93.7% 
in the presence of 10 µM of the known tubulin binder VCR but remains unaltered in the 
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presence of 5 µM of the known actin binder JAS (Figure 4.7). In contrast, the three annulated 
indoles, which increased the mitotic index of HL-60 tumor cells, are also capable of 
inhibiting the polymerization of tubulin in the cell-free turbidity assay, albeit requiring higher 
concentrations. 
 
Reproduced with permission from [Anticancer Res 2014, 34, 1643] 
Figure 4.6. Comparison of the ability of anti-proliferative KU-72, KU-80 and KU-70, 
jasplakinolide (JAS) and the known microtubule destabilizing anticancer drug vincristine 
(VCR) to alter the kinetics of glycerol-induced tubulin polymerization in vitro. The 
polymerization reactions were incubated in the presence or absence (control) of 10 µM VCR, 
48, 120 or 300 µM KU-72, 300 µM KU-80, 120 µM KU-70, and 5 µM JAS. Results are 
expressed as the percentage of the rate of glycerol-induced tubulin polymerization based on 
the linear increase in turbidity between 80 and 520 s in vehicle-treated control assays 
(ΔA340 nm=0.190±0.012; 100±6.6%). Data are means±SD (n=2). A Not different from 
control; bp<0.05, significantly less than control. 
 
The study concluded that the annulated indoles appear to interact with both tubulin to 
reduce microtubule assembly and actin to block cytokinesis, thereby inducing bi- and 
multinucleation, resulting in genomic instability and apoptosis. 
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CHAPTER 5 
 
DESIGN AND SYNTHESIS OF NOVEL 4-, 5-, 6,7 BENZANNULATED 
TRIBROMO SCAFFOLDS FOR CROSS-COUPLED LIBRARIES 
A recent perspective by Taylor reveals that the indole nucleus is the 24th most 
frequently used ring system from small molecule drugs (before 2013) listed in the FDA 
Orange Book (Taylor, MacCoss et al., 2014). A recent study revealed that the indole-
containing natural products and derivatives provide an opportunity to control unwanted 
bacterial behaviors, such as virulence, biofilm formation, antibiotic resistance, and persister 
formation as an alternative therapeutic strategy to simply killing bacteria, and may result in a 
reduced evolutionary pressure for resistance development (Melander, Minvielle et al., 2014). 
These reports indicate the potential and increasing relevance of the indole nucleus in 
therapeutic efforts. Therefore our ultimate goal is to synthesize a diverse collection of indole 
containing molecules for their therapeutic assessment.  
5.1: Metal Halogen Exchange-Induced Indole Aryne Generation 
Towards these efforts, our group developed a selective metal halogen exchange 
methodology (Scheme 1) on the indole nucleus of the 4-, and 5-, 6,7-tribromoindole nucleus 
(Buszek et al., 2) This methodology has already demonstrated its value in the total synthesis 
of benzannulated indole natural products as well as in production of the first benzannulated 
indole libraries (Sheme 3.1). The selective metal halogen exchange was demonstrated by first 
N-protecting the tribromoindoles (MeI (2.0 equiv.; NaH, 2.0 equiv.; THF, 0 °C)). The N-
Methylated 4-, and 5-, 6,7-tribromoindoles were subjected to the metal-halogen 
exchange/elimination protocol with n-BuLi (2.0 equiv.; PhMe, -78 °C) (Buszek, Brown et 
al., 2009). After 15 minutes at that temperature the reaction mixture was quenched with 
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water to give 5,6-dibromoindole 5.10 (55 %) and some unreacted starting material 4.84 
(Scheme 5.1). The analysis by NMR revealed no cycloaddition was achieved at -78 oC and 
only the reduced 7-hydro indole, 5.10b was recovered, which confirmed selective metal-
halogen exchange took place exclusively at C-7 position in both tribromoindoles systems. 
However, upon warming the reaction from -78 oC to -40 oC under the same 
conditions before quenching, the metal halogen by-product (LiBr) was eliminated, 
consequently generating a powerful and versatile dienophile that underwent cycloaddition 
with cyclopentadiene and other suitable dienes as expected.  
	  
Scheme 5.1: Metal Halogen Exchange Experiment 
 
The 6,7-indole aryne was also trapped with substituted dienes such as tert-butyl furan, 
and showed a remarkable regioselectivity (Brown, Luo et al., 2009; Garr, Luo et al., 2010). 
These observations prompted an investigation on the fundamental electronic and steric 
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parameters that account for these fascinating reaction profiles. These calculations were 
employed by Cramer and Garr to predict the structures and reactivities of the N-methyl-4,5-, 
5,6-, and 6,7-indolynes with furan and 2-alkylfurans. In this methodology, all structures were 
optimized using the M06-2X density functional (Zhao and Truhlar, 2008) and 6-
311+G(2df,p) basis set (Hehre, Radom et al., 1986) as implemented in MN-GFM (Zhao and 
Truhlar, 2008), a locally modified version of the Gaussian03 software package (Frisch, 
Trucks et al., 2004). Analytical frequency calculations were employed to characterize the 
nature of all gas-phase structures as minima or transition states. In some instances, the effects 
of diethyl ether solvation were taken into account using the SMD implicit solvation model 
(Marenich, Cramer et al., 2009; Marenich, Hawkins et al., 2008). Similar calculations were 
also performed for the benzofuran and benzothiophene analogues of the indolynes. This 
theoretical and computational investigation studies showed the 6,7-aryne bond was polarized 
as being electrophilic at C6 and nucleophilic at C7 (Figure 5.1) (Chandrasoma, Brown et al., 
2013). The effects of indole substitutions on regioselectivity were also investigated and 
reported (Nerurkar et al. 2013). 
 
Figure 5.1: Polarized nature of the 6,7-indole aryne 
This revelation helped to explain the remarkable regioselectivity in the 6,7-indole 
aryne cycloaddition with 2-substituted furans. Based on the theoretical studies it is evident 
that the dipolar effects can induce regioselection with asymmetrically substituted dienes 
when polarization of the benzyne triple bond imparts substantial asynchronous electrophilic 
substitution character to the initial bond forming step. 
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In an effort to expand the utility of our indole aryne cycloaddition tactic and create 
indole-based scaffolds of increasing topological complexity, we decided to incorporate a 
ring-opening metathesis/ring-closing metathesis (ROM/RCM) sequence to our previous 
strategy in order to create a set of twelve new scaffolds (scaffold types I-IV, Scheme 1).  In 
this manner an additional seven- or eight-membered ring is generated that effectively tethers 
the indole nitrogen to the benzannulated entity. The remaining Ar-Br bond at either the 4- or 
5-position is then available for various Pd(0)-catalyzed cross-coupling reactions (e.g., 
Buchwald-Hartwig, Negishi, Suzuki-Miyaura) as we previously demonstrated (Brown, 
Buszek et al, 2009). Furthermore, the resulting vinyl moiety might be subsequently 
hydroaminated by any of several attractive methods (Utsunomiya, Kuwano et al., 2003; 
Utsunomiya, Hartwig et al., 2003,2004; Hartwig, Utsunomiya et al., 2005; Munro-Leighton, 
Delp et al., 2007,2008; Brinkmann, Barrett et al., 2012). 
Another benefit of these scaffolds is that the endocyclic olefin offers the potential for further 
functionalization. We now report the first examples of polycyclic, benzannulated indole 
scaffolds linked through the indole nitrogen, reminiscent of the ones shown in scheme 5.2 
below. 
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Figure 5.2: The four basic types of polycyclic indole scaffolds. 
The synthesis of the scaffolds began with either 4,6,7-tribromoindole 5 (for types I 
and III), or 5,6,7-tribromoindole 6 (for types II and IV), both of which were previously 
synthesized by us on a multi-gram scale via modifications of the Bartoli (Dalpozzo and 
Bartoli, 2005) and Leimgruber-Batcho (Lloyd, Nichols et al., 1986; Mayer, Cassady et al., 
1990; Leze, Palusczak et al., 2008) indole synthesis methods, respectively. 
5.2: Synthesis of 4,6,7-Tribromoindole 
Synthetic efforts of the desired 4,6,7-tribromoindole started with a commercially 
available o-nitroaniline 3.1 which was first brominated at C2 and C4 (HBr , MeOH/CH2Cl2, 
90%), followed by diazotization to afford the 2,3,5-tribromonitrobenzene 3.3. Application of 
the Bartoli reaction conditions (vinyl magnesium bromide, 6.0 equiv, tetrahydrofuran (THF), 
-40 oC) consistently gave the desired indole, 3.4 in 45% yield on up to more than 50 g scale. 
We needed to protect the indole nitrogen, which was achieved by reacting the 4,6,7-
  38 
tribromoindole with TBSOTf, (3.0 equiv.; NaH, 4.0 equiv.; Et3N, 2.0 equiv.; THF; 0 °C) to 
give the desired N-protected tribromoindole constantly in 72-78% yield.  
 
Scheme 5.2: Bartoli Indole Synthesis of the N-TBS protected 4,6,7-tribromoindole 
5.3: Synthesis of 5,6,7-Tribromoindole via Bartoli- Indole Synthesis 
Due to the success and scalability of the 4,6,7-tribromoindole synthesis via Bartoli 
reaction conditions, we viewed that the Bartoli reaction protocol (Dalpozzo and Bartoli, 
2005) would afford the shortest and easiest pathway to access the 5,6,7-tribromoindole 4.84. 
Thus, our initial approach of the synthesis commenced with commercially available 2,6-
dibromoaniline 4.81.  Diazotization with t-BuONO (1.6 equiv.) and bromination with CuBr2 
(1.3 equiv.) (Doyle, Van Lente et al., 1980), (MeCN, 60 °C) (Menzel, Fisher et al., 2006) 
gave 1,2,3-tribromobenzene 4.82 in 80% yield. Nitration with fuming nitric acid in 1,2-
dichloroethane gave exclusively 1,2,3-tribromo-4-nitrobenzene 4.83 in 82% yield (Scheme 
5.3). Unfortunately application of the Bartoli reaction conditions (CH2=CHMgBr, 6.0 equiv.; 
THF, -40 °C) provided the desired 5,6,7-tribromoindole 4.84 in only 32% yield. Many 
attempts to optimize the conditions to improve the yield were unsuccessful.  
	  
Scheme 5.3: Bartoli Indole Synthesis of the 5,6,7-tribromoindole 
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5.4: Leimgruber-Batcho Indole Synthesis of the 5,6,7-Tribromoindole 
Alternatively, we elected to use Leimgruber-Batcho indole synthesis (Lloyd, Nichols 
et al., 1986; Mayer, Cassady et al., 1990; Leze, Palusczak et al., 2008). Synthetic efforts 
started with commercially available and inexpensive p-toluidine, 4.85 that was brominated in 
situ (HBr, 3.0 equiv.; H2O2, 2.0 equiv.; MeOH) (Barhate, Gajare et al., 1999) to provide 4.86 
in nearly quantitative yield (Scheme 5.4). The aniline 4.86 was converted to 1,2,3-tribromo-
5-methylbenzene 4.87 in 80% yield via the diazotization and bromination protocol as shown 
earlier. Nitration was achieved, as before, with fuming nitric acid (2.0 equiv.) to give the 
1,2,3-tribromo-5-methyl-4-nitrobenzene 4.88. Reaction of 4.88 with tri(piperidin-1-
yl)methane, 4.89  (1.5 equiv., 105 °C, 15 torr) gave the enamine intermediate, 4.90 which 
was used without purification in the iron catalyzed reductive cyclization step to generate the 
desired indole 4.84 in 61% yield over 2 steps.  
The Leimgruber-Batcho approach was found to be very useful as it was also highly 
scalable at least upto 30 g and consistently gave the desired indole in 60-61% yield. The 
indole nitrogen was protected as its N-TBS ether as before to afford the NTBS-protected 
5,6,7-tribromoindole, 6.22. 
	  
	  
Scheme 5.4: Leimgruber-Batcho Indole Synthesis of the N-TBS protected 5,6,7-tribromo 
indole 
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5.5: Original Approach to Synthetic Scheme of Scaffolds Type 1 and 3 
With the key N-TBS protected 4,6,7-tribromoindole, 4.70 in hand, and the 
demonstrated selective metal halogen exchange (Buszek, Luo et al., 2007; Brown, Luo et al., 
2009; Thornton, Brown et al., 2011; Nerurkar, Chandrasoma et al., 2013). The 6,7-indole 
aryne was generated by reaction with n-butyllithium (1.6 M in hexanes,1.2 equiv) in toluene 
at -78 °C to effect a selective C-7 lithium-halogen exchange followed by elimination upon 
warming to -40 °C. Reaction with excess cyclopentadiene gave the corresponding 
cycloadduct 4.73 in 78% yield. Indole nitrogen was desilylated (TBAF, 2.0 equiv.; THF; 0 
oC) to give the corresponding N-deprotected cycloadduct 4.74 in 90% yield. To achieve the 
desired ring size on the final scaffolds, the indole nitrogen was re-protected (allyl bromide, 
3.0 equiv; NaH, 4.0 equiv; catalytic tetrabutyl ammonium iodide (TBAI) 0.5 mol%; THF, 
room temperature) to afford the corresponding N-allylated cycloadduct 4.75 in 90% yield 
(Scheme 5.5). Ring opening metathesis (ROM)/ring closing metathesis (RCM) was achieved 
via reaction of 4.75 with Grubbs’ first-generation catalyst (5 mol%; PhMe; 110 °C; 0.5 h) 
followed by the ruthenium scavenger P(CH2OH)3, 4.0 equiv.; Et3N; MeOH; room 
temperature) to give the type 1 cyclopentadiene scaffold  1a in 45% yield. Scaffold type III 
followed similar scheme with the exception of the N-alkylation step where homoallyl 
bromide was used instead of allyl bromide (Scheme 5.5b). 
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Scheme 5.5: Original Approach to Polycyclic benzannulated Indole Scaffolds Type 1 
 
 
Scheme 5.5b: Original Approach to Polycyclic benzannulated Indole Scaffolds Type 3 
 
5.6: N-alkylation of the Tribromo Indoles 
However, we were interested in investigating if the N-allylated cycloadduct 3.41 
would undergo selective metal halogen exchange as demonstrated by the N-TBS protected 
indoles. This investigation was appealing as it would eliminate the N-TBS protection and 
desilylation steps in the synthesis. Thus, the tribromoindole 3.4 was first N-allylated (allyl 
bromide, 3.0 equiv; NaH, 4.0 equiv; catalytic tetrabutylammonium iodide, TBAI, 0.5 mol%; 
THF, room temperature) to afford the corresponding product 3.41 in 90% yield (Scheme 
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5.6). The N-alkylation of scaffolds types III and IV proceeded in moderate yields despite 
numerous attempts to optimize reaction conditions such as longer reaction times, different 
solvents, varying catalyst loading and elevated temperatures. Starting material was recovered 
in all cases and required re-running the experiment multiple times. Despite this shortcoming, 
fewer steps to the desired scaffolds were more attractive as the overall yield of the scaffolds 
was synthetically useful compared to the original approach. 
 
Scheme 5.6: Alternative N-alkylation of the 4- and 5-, 6,7-tribromo indoles  
Gratifyingly, these N-alkylated 4-, and 5-, 6,7-tribromoindoles demonstrated high 
propensity to undergo metal halogen exchange (scheme 5.7). The 6,7-indole aryne was 
generated by reaction with n-butyllithium (1.6 M in hexanes, 2.0 equiv) in toluene at -78 °C 
to effect a selective C-7 lithium-halogen exchange followed by elimination upon warming to 
-40 °C.  
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Scheme 5.7: Cycloaddition reactions of the N-alkylated tribromoindoles 
5.7: Second Generation Synthesis of Scaffold Type 1 
Gratified with the successful accomplishment of the cycloadditions, we designed and 
executed the second generation synthesis of scaffold type I (scheme 5.8). Starting with the 
4,6,7-tribromoindole 3.4, N-allylation was achieved as before (scheme 5.7) to afford the 
corresponding N-allylated tribromo indole product (scheme 5.8, 3.41). The 6,7-indole aryne 
was generated as before by reaction with n-butyllithium (1.6 M in hexanes, 1.2 equiv) in 
toluene at -78 °C to effect a selective C-7 lithium-halogen exchange followed by elimination 
upon warming to -40 °C. Reaction with cyclopentadiene gave the corresponding cycloadduct 
3.44 in 67% yield. Grubb’s catalyst was used to effect ring opening of the strained 
cyclopentene ring. The relieve of this strain reveals two terminal olefins, one of which is in 
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close proximity to the N-allylated terminal olefin and sets up subsequent ring closing 
metathesis reaction to yield the desired scaffold of type 1a. 
 
Scheme 5.8: Second Generation Synthesis of Type 1 benzannulated indole scaffolds via 6,7-
indole aryne Cycloaddition and ROM/RCM. 
 
5.8: Ring Opening/Ring Closing Metathesis 
 A one-pot ring opening metathesis (ROM)/ring closing metathesis (RCM) reaction was 
attractive. The versatility of the Grubbs’ catalyst had already been demonstrated in the 
syntheses of another library and noted that they had an advantage in their ability to tolerate a 
variety of functional groups in a substrate (Brown, Xie et al., 2008). We envisioned a quick 
access to our desired polycyclic template, by the initial ring opening driven by strain relieve 
of the olefinic cyclopentenoid ring. This results in another benzannulated cyclopentenoid ring 
possessing two cis-stereogenic centers and two terminal olefins that are essential for Grubbs’ 
ring closing metathesis (scheme 5.9). Upon coming into contact with the Grubb’s catalyst, 
the olefinic indole nitrogen tether with a terminal olefin pairs up with the terminal olefin in 
its vicinity to effect the ring closing metathesis as depicted below. 
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Scheme 5.9: Postulated sequence of the ring opening metathesis/ring closing metathesis 
ROM/RCM 
 
 Thus, ROM/RCM (first or second generation Grubbs’ catalyst (5 mol %); PhMe; 110 °C; 
0.5 h, followed by the Ruthenium-scavenger, P(CH2OH)3, 4.0 equiv.; Et3N; MeOH, room 
temperature) gave the scaffold type 1a (45%).  The remaining two type I scaffolds 1b and 1c 
were prepared in a parallel fashion using furan and 2,5-dimethylfuran respectively to give the 
desired products in 40% and 38% yields from their respective cycloadducts. The synthesis of 
the Type II scaffolds proceeded in a similar fashion starting with the 5,6,7-tribromoindole 
4.84.  
 In the same manner, the corresponding polycyclic eight-membered scaffolds (Types 3 and 
4) were obtained using the homoallyl bromide in place of allyl bromide (Scheme 5.91).  Thus 
3.4 and 4.84 were N-alkylated with 4-bromo-but-1-ene in 45-70% yield. Each of the N-
alkylated tribromoindoles was then subjected to [4+2] cycloadditions with cyclopentadiene, 
furan and 2,5-dimethylfuran to yield the corresponding cycloadducts. Grubbs’ ROM/RCM 
sequence gave the desired scaffolds of types 3 and 4 (Scheme 5.91). 
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Scheme 5.91: Synthesis of the Type IV benzannulated indole scaffolds via 6,7-indole aryne 
cycloaddition and ROM/RCM. 
 
5.9: Cross-coupling reactions 
To diversify our scaffold types 1 to 4, and validate their application in library 
development, the extra bromine on the scaffolds was subjected to Suzuki-Miyaura or 
Buchwald-Hartwig conditions as before (Brown, Buszek et al 2009). Thus, the polycyclic 
benzannulated scaffolds of types 1 to 4 were reacted with a collection of commercially 
available inexpensive secondary amines (Buchwald-Hartwig) and boronic acids (Suzuki-
Miyaura) reagents.  With this approach, we envisioned that if we use only 4 amines and 4 
boronic acids per scaffold, our target library would afford at least 192 (12 x 4 x 4) library 
members with enough diversity to prompt a possible Hit-to-Lead success. Schemes 5.92 and 
5.93 illustrate the synthetic approach of some of the scaffold types 1 to 4 using some of the 
cross-coupling reagents and demonstrate the versatility of these core scaffolds. 
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Scheme 5.92: Specific examples of library members from scaffolds types 1 and 3. 
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Scheme 5.93: Specific examples of a library from scaffolds types 2 and 4. 
5.91: Future Directions 
Olefins are prevalent in natural products and are important functional groups in 
organic synthesis, mainly due to their reliability to be modified into a great diversity of other 
functional groups. The ubiquity of nitrogen atoms in natural and synthetic products 
especially drugs validates the reasons to investigate methods to functionalize the two unique 
olefins on these scaffolds. Literature documents existing methods for functional group 
interconversion of different types of olefins, specifically; un-activated, strained, electron rich 
and electron deficient olefins towards epoxidation, cross-metathesis and hydroamination, 
hydroamidation among others (Utsunomiya, Kuwano et al., 2003; Utsunomiya, Hartwig et 
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al., 2003,2004; Fontaine and Tilley, 2005; Karshtedt, Bell et al., 2005; Hartwig, Utsunomiya 
et al., 2005; Munro-Leighton, Delp et al., 2007,2008; Brinkmann, Barrett et al., 2012; Strom, 
Hartwig et al., 2013). Successful adaptation of these several attractive approaches especially 
to selectively distinguish the endocyclic from the exocyclic olefin would be investigated in 
order to further diversify these scaffolds.  
Construction of carbon-nitrogen bond for instance, is gaining considerable interest 
due to its atom efficiency (Beller, 1999). This research has led to availability of different 
methods for introducing carbon-nitrogen bonds including catalytic amination of olefins to 
yield primary, secondary and tertiary amines. Another method is intermolecular oxidative 
amination of aromatic olefins to give enamines (Beller, Eichberger et al., 1997). Other 
reagents and catalysts that selectively yield Markovnikov and anti-Markovnikov products 
have also been reported (Beller, Trauthwein et al., 1999; Munro-Leighton, Delp et al., 2008), 
in which adaptation of such catalysts would greatly diversify these scaffolds as illustrated in 
scheme 5.94.  
 
Scheme 5.94: Functionalization of olefins to yield Markovnikov and anti-
Markovnikov library members 
 
Once these Markovnikov and anti-Markovnikov scaffolds are obtained, a collection 
of pharmaceutically useful functional groups could be obtained by functionalizing the 
secondary amine to afford carbamates, ureas, and sulfonamides among others. These efforts 
would result in very unique library members that would be expected to occupy regions of 
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sparsely occupied regions of chemical and biological property space; a highly desired trait in 
library development. 
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CHAPTER 6 
EXPERIMENTAL SECTION 
6.1 General Details 
1H-NMR (400 MHz) and 13C-NMR (101 MHz) were performed in CDCl3 unless 
otherwise noted with reference to residual solvent at δ 7.26 ppm and 77.0 ppm respectively.  
Melting points reported are uncorrected.  Unless otherwise noted, all commercially obtained 
starting materials were used as received.  N-butyllithium was titrated against 2-butanol in 
anhydrous THF with 1,10-phenanthroline as an indicator prior to use.  Tetrahydrofuran and 
diethyl ether were distilled from sodium and benzophenone under nitrogen prior to use.  
Toluene was distilled from calcium hydride under nitrogen prior to use.  Temperatures of -78 
°C were obtained through use of a dry-ice acetone cold bath. Microwave reactions were 
carried out using a Biotage Initiator microwave reactor at the times and temperatures 
indicated. 
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6.2. EXPERIMENTAL PROCEDURES 
6.21: Synthesis of 4,6,7-Tribromoindole Via Bartoli Indole Synthesis 
 
 
1,2,3-tribromobenzene (4.82): In a 500 mL round-bottom flask was dissolved 5.78 g (25.9 
mmol) CuBr2 in 200 mL CH3CN and heated to 60 oC. To the hot solution was added 3.8 mL 
(32 mmol) tert-butyl nitrite followed by a solution of 5.0 g (20 mmol) 4.81 in 50 mL CH3CN. 
The mixture was stirred at 60 oC for 1 h, then cooled to room temperature and poured into 
200 mL 20% aqueous ammonia. The mixture was extracted with hexane (2 x 200 mL) and 
the combined organic phase was washed with 20% aq. NH3 (100 mL), water (100 mL), brine 
(50 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under reduced 
pressure. The crude material was recrystallized from ethanol to give 5.12 g (82%) of 4.82 as 
off white solid. MP: 88-90. 1H NMR (400MHz, CDCl3): δ 7.58 (d, J = 8.0 Hz, 2 H), 7.03 (t, J 
= 8.0 Hz, 1 H); 13C NMR (CDCl3): δ 132.6, 129.2, 127.7, 126.2.  The physical and spectral 
data is consistent with that which was previously reported for this compound (Menzel, 
Fisher, et al., 2006; Teclechiel, Sundstroem et al., 2009) 
 
 
 
  53 
 
1,2,3-Tribromo-4-nitrobenzene (4.83): In a 250 mL round-bottom flask was dissolved 5.02 
g (15.9 mmol) of 4.82 in 100 mL 1, 2-dichloroethane and cooled to 0 oC To the vigorously 
stirred solution at 0 oC was added 7.0 mL (159 mmol) fuming HNO3 dropwise over 15 
minutes. The mixture was stirred at 00 C for 1 h and was poured into 500 mL ice. After 30 
minutes, 100 mL of CH2Cl2 was added and the mixture was washed with water (3 x 100 mL), 
NaHCO3 (3 x 100 mL), brine (100 mL), dried over anhydrous magnesium sulfate, filtered 
and concentrated under reduced pressure. The crude material was recrystallized from hexanes 
to give 4.74g (83%) of 4.83 as an off-white solid. MP: 82-84 oC 1H NMR (400MHz, CDCl3): 
δ 7.76 (d, J = 8.6 Hz, 1 H), 7.51 (d, J = 8.6 Hz, 1 H); 13C NMR (CDCl3): δ 132.6, 132.5, 
131.1, 130.1, 123.7, 118.7; HRMS (EI) m/e calcd for C6H2Br3NO2 356.7635, found 
356.7633. This compound has been reported in the literature, but no spectral or physical data 
except melting point was given: Chen, Konstantinov et al, 2001) 
 
 
 
4,6,7-tribromo-1H-indole (3.4): In 250 mL round-bottom flask was dissolved 2.0 g (5.6 
mmol) 4.83 in 20 mL THF and cooled to -40 oC. To the vigorously stirred solution was 
added 16.7 mL (16.7 mmol) 1M vinyl magnesium bromide via syringe at once. The mixture 
was stirred for 1h. The mixture was quenched with 100 mL saturated NH4Cl. The mixture 
was extracted with diethyl ether (2 x 100 mL) and the combined organic phase was washed 
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with water (100 mL), brine (50 mL), dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 10% EtOAc in hexanes as eluent to give 0.628 g (32%) 
of 3.4 as a white solid. MP: 132-134oC. 1H NMR (400MHz, CDCl3): δ 8.36 (br. s., 1 H, 
NH); 7.89 (s, 1 H); 7.27 (dd, J = 3.32, 3.32 Hz, 1 H); 6.57 (dd, J = 3.32, 3.32 Hz, 1 H). 13C-
NMR: δ 134.80, 128.20, 126.42, 124.01, 119.17, 115.45, 107.93, 103.54. HRMS (EI) m/e 
calcd for C8H4Br3N 350.7894, found. 
 
 
 
 
4,6,7-tribromo-1-(tert-butyldimethylsilyl)-1H-indole (4.70): C14H18Br3NSi, Molecular 
Weight: 468.10 g/mol. In a flame-dried 250 mL three-necked round bottom flask under argon 
was added a solution of 1.00 g (2.82 mmol) 3.4 in 50 mL dry THF. To this was added 0.271 
g (11.3 mmol) of NaH followed by 0.80 mL (5.6 mmol) Et3N. The resulting suspension was 
cooled to 0 oC, after 15 min at 0 oC, 0.92 mL (5.6 mmol) of tert-butyldimethylsilyl 
trifluoromethanesulfonate diluted in 5 mL pentane was added dropwise via syringe over 5 
min. The solution was stirred at 0 oC for 20 minutes. The reaction was then diluted with 
diethyl ether (50 mL) and quenched by addition of saturated NH4Cl (100 mL). Then the 
mixture was extracted with diethyl ether (3 x 100mL). The combined organic phase was 
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude material was then purified via column chromatography on silica gel using 1% 
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methyl tert-butyl ether in hexanes as eluent to give 1.03 g (78%) of 4.70 as colorless oil 
which solidified at room temperature. 1H NMR (400MHz, CDCl3): δ 7.85 (s, 1 H); 7.41 (d, J 
= 3.32 Hz, 1 H); 6.57 (d, J = 3.32 Hz, 1 H); 0.97 (s, 9 H); 0.72 (s, 6H).   13C-NMR: δ 140.47, 
136.20, 133.80, 123.71, 121.31, 116.29, 109.74, 104.99, 27.37, 19.91, 2.19.  
 
 
 
4-bromo-1-(tert-butyldimethylsilyl)-6,9-dihydro-1H-6,9-methanobenzo[g]indole (4.73): 
In a flame-dried 250 mL three- necked round-bottom flask under argon was added a solution 
of 4.70, 0.610 g (1.30 mmol) in dry toluene (60 mL). To this was added 1.72 g (26.0 mmol) 
of freshly cracked cyclopentadiene. The resulting solution was cooled to -78 oC, then 1.04 
mL (2.60 mmol) of a 2.5 M solution of n-butyl lithium in hexanes was added dropwise via 
syringe over 15 min. The solution was stirred at -78 oC for 30 min then allowed to slowly 
warm to room temperature. The reaction was then quenched by addition of saturated NH4Cl 
(50 mL). After stirring for 5 minutes, the mixture was diluted with water (100 mL) and 
extracted with diethyl ether (3 x 100 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 1% methyl tert-
butyl ether in hexanes as eluent to give 0.380 g (78%) of 4.73 as a colorless liquid. 1H NMR 
(400MHz, CDCl3): δ 7.33 (s, 1 H); 7.22 (d, J = 3.37 Hz, 1 H); 6.92 (dd, J = 3.08, 5.12 Hz, 1 
H); 6.83 (dd, J = 2.93, 4.83 Hz, 1 H); 6.63 (d, J = 3.37 Hz, 1 H); 4.47 (bs, 1 H); 3.98 (bs, 1 
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H); 2.34 (m, 1 H); 2.26 (m, 1 H); 1.03 (s, 6 H); 0.65 (s, 3 H); 0.60 (s, 3 H).  13C-NMR: δ 
148.6, 145.0, 142.0, 136.9, 134.2, 132.5, 130.8, 118.6, 109.2, 105.4, 70.4, 51.0, 50.6, 26.6, 
19.4, -1.4, -1.8. HRMS (EI) m/e calcd for C19H24BrNSi 373.0861, found  
 
 
 
4-bromo-6,9-dihydro-1H-6,9-methanobenzo[g]indole (4.74): In a flame-dried 100 mL 
three- necked round-bottom flask under argon was added a solution of 4.73 (0.170 g, 0.460 
mmol) in 5 mL dry tetrahydrofuran (THF). The solution was cooled to 0 oC for 10 mins. To 
this was added 1.0 M tetrabutylammonium fluoride (TBAF) (0.92 mL 0.92 mmol) dropwise. 
Reaction was then followed by TLC and showed completion after 5 mins. The reaction was 
then quenched by addition of saturated NH4Cl (5 mL). The reaction was then extracted with 
diethyl ether (2 x 5 mL) and the combined organic phase dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
purified via column chromatography on silica gel using 30% dichloromethane in hexanes as 
eluent to give 0.116 g (97%) of 4.74 as a foamy white solid. 1H NMR (400 MHz, CDCl3): δ 
8.05 (br. s., 1H), 7.31 (s, 1H), 7.19 (dd, J = 2.5, 3.4 Hz, 1H), 6.90 (dd, J = 2.9, 5.3 Hz, 1H), 
6.83 (dd, J = 2.9, 5.3 Hz, 1H), 6.55 (dd, J = 2.0, 3.5 Hz, 1H), 4.15  (br. s., 1H), 4.01 (br. s., 
1H), 2.41 (dt, J = 1.6, 6.9 Hz, 1H), 2.33 (dt, J = 1.4, 6.7 Hz 1H).  13C-NMR: δ 148.2, 144.6, 
142.0, 133.0, 131.7, 126.9, 124.6, 118.2, 109.0, 103.4, 71.7, 50.8, 47.4.  
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1-allyl-4-bromo-6,9-dihydro-1H-6,9-methanobenzo[g]indole (4.75): In a flame-
dried 100 mL round-bottom flask under argon was added a solution of 4.74 (250 mg, 0.970 
mmol) in dry tetrahydrofuran (20 mL). To the solution was added sodium hydride (92.6 mg, 
3.86 mmol) and catalytic Tetrabutylammonium iodide (1.8 mg, 0.005 mmol). The solution 
was then cooled to 0 oC for 10 min. To this was added allyl bromide (0.25 mL, 2.91 mmol) 
dropwise. TLC analysis showed completion after 30 min. The reaction was then quenched by 
addition of saturated NH4Cl (20 mL). The reaction was then extracted with diethyl ether (2 x 
10 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered 
and concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to afford 
4.75  (261 mg, 90%) as a yellowish oil. 1H NMR (400MHz, CDCl3): δ 7.37 (s, 1H), 7.04 (d, 
J = 3.5 Hz, 1H), 6.93 (dd, J = 2.9, 5.3 Hz, 1H), 6.85 (dd, J = 2.9, 5.3 Hz, 1H), 6.55 (d, J = 3.2 
Hz, 1H), 6.09 (tdd, J = 4.5, 10.4, 17.1 Hz, 1H), 5.25 (dd, J = 1.3, 10.4 Hz, 1H), 4.95 - 4.81 
(m, 3H), 4.38 (br. s., 1H), 4.03 (br. s., 1H), 2.45 - 2.35 (m, 2H). 13C NMR (101MHz, CDCl3): 
δ 148.45, 144.38, 142.80, 133.98, 132.67, 132.25, 129.21, 127.78, 117.91, 116.48, 109.18, 
101.88, 71.23, 50.41, 50.22, 48.27. HRMS (EI) m/e calcd for C16H14BrN 300.20, found.  
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4-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-methanobenzo[g]indole (3.46): In a 
flame-dried 100 mL round-bottom flask under argon was added a solution of 4.74 (250 mg, 
0.970 mmol) in dry tetrahydrofuran (20 mL). To the solution was added sodium hydride 
(92.6 mg, 3.86 mmol) and catalytic tetrabutylammonium iodide (1.8 mg, 0.005 mmol). The 
solution was then cooled to 0 oC for 10 min. To this was added Homo-allyl bromide (4-
bromo-1-butene) (0.30 mL, 2.91 mmol) dropwise. TLC analysis showed completion after 1 
h. The reaction was then quenched by addition of saturated NH4Cl (20 mL). The reaction was 
then extracted with diethyl ether (2 x 10 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 5% methyl tert-
butyl ether in hexanes as eluent to afford 3.46 (249 mg, 82%) as a clear oil that solidifies at 
room temperature. 1H NMR (400MHz, CDCl3): δ 7.29 (s, 1 H), 7.01 (d, J = 3.2 Hz, 1 H), 
6.89 (ddd, J = 18.1, 5.2, 3.1 Hz, 2 H), 6.44 (d, J = 3.2 Hz, 1 H), 5.80 (ddt, J = 17.1, 10.2, 6.8 
Hz, 1 H), 5.15 - 5.08 (m, 2 H), 4.38 (br. s., 1 H), 4.37 - 4.22 (m, 2 H), 4.00 (br. s., 1 H), 2.61 
- 2.54 (m, 2 H), 2.38 (ddt, J = 17.8, 6.7, 1.6 Hz, 2 H). 13C-NMR (125 MHz): δ 148.2, 144.8, 
142.3, 134.2, 132.4, 132.0, 129.1, 127.9, 117.9, 117.6, 109.4, 101.7, 71.3, 50.5, 48.4, 47.9, 
35.6.  
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(2S,9aR)-4-bromo-2-vinyl-1,2,7,9a-tetrahydro-6a-azacyclohepta[jkl]-as-indacene (1a): 
In a 25 mL dry sealed tube was added a solution of 3.44 (0.150 g (0.500 mmol) in CH2Cl2 (5 
mL). The solution was stirred and purged with argon. To the solution was added Grubbs’ 
first generation catalyst (20.6 mg, 0.025 mmol) and refluxed for 0.5 h. TLC analysis showed 
completion of the reaction. The reaction was cooled to r.t. and the ruthenium scavenger; tris 
(hydroxymethyl)-phosphine (0.248 g, 2.00 mmol) dissolved in methanol (2 mL) and Et3N 
(0.5 mL) was added to the solution and stirred overnight. H2O (5 mL) was then added and 
stirred vigorously for 0.5 h. With the phases separated, the organic layer was washed with 
brine (5 mL) and dried over anhydrous MgSO4. The solution was then filtered and 
concentrated under reduced pressure to afford a dark brown to black oil. Flash 
chromatography was achieved using silica gel and eluting with 40% tert-butyl methyl ether 
in hexanes to give 1a (0.068 g, 45%) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 7.04 
(s, 1H), 6.99 (d, J = 2.9 Hz, 1H), 6.41 (d, J = 3.2 Hz, 1H), 6.12 - 6.07 (m, 1H), 6.04 - 5.96 
(m, 1H), 5.82 (ddd, J = 8.8, 10.0, 17.0 Hz, 1H), 5.27 (ddd, J = 0.7, 1.8, 17.1 Hz, 1H), 5.20 - 
5.12 (m, 2H), 4.39 (dd, J = 8.2, 14.6 Hz, 2H), 3.89 - 3.81 (m, 1H), 2.71 (td, J = 7.1, 12.1 Hz, 
1H), 1.79 (td, J = 10.7, 12.2 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 140.48, 140.01, 138.90, 
134.11, 128.10, 127.86, 126.15, 123.60, 118.88, 116.06, 112.58, 100.85, 49.45, 45.82, 41.75, 
40.53. 
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(2S,10aR,Z)-4-bromo-2-vinyl-2,7,8,10a-tetrahydro-1H-6a-azacycloocta[jkl]-as-indacene 
(3a): In a 25 mL dry sealed tube was added a solution of 3.46 (0.060 g (0.019 mmol) in 
CH2Cl2 (3 mL). The solution was stirred and purged with argon. To the solution was added 
Grubbs’ second-generation catalyst (0.008 mg, 0.010 mmol) and refluxed for 0.5 h. TLC 
analysis showed completion of the reaction. The reaction was cooled to r.t. and the ruthenium 
scavenger; tris (hydroxymethyl)-phosphine (0.094 g, 0.760 mmol) dissolved in methanol (0.8 
mL) and Et3N (0.2 mL) was added to the solution and stirred overnight. H2O (3 mL) was 
then added and stirred vigorously for 0.5 h. With the phases separated, the organic layer was 
washed with brine (3 mL) and dried over anhydrous MgSO4. The solution was then filtered 
and concentrated under reduced pressure to afford a dark brown to black oil. Flash 
chromatography was achieved using silica gel and eluting with 40% tert-butyl methyl ether 
in hexanes to give 3a (0.024 g, 42.0%) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 
7.06 (s, 1H), 7.02 (d, J = 3.2 Hz, 1H), 6.48 (d, J = 3.2 Hz, 1H) 5.86 (ddd, J = 8.5, 10.0, 17.0 
Hz, 1H), 5.68 (ddt, 1H), 5.50 - 5.43 (m, 1H), 5.09 (td, J = 1.3, 17.0 Hz, 1H), 5.00 (dd, J = 
2.0, 10.0 Hz, 1H), 4.83 (ddd, J = 2.0, 12.6, 14.9 Hz, 1H), 4.62 (dtd, 1H), 4.13 (td, J = 4.1, 
14.9 Hz, 1H), 3.85 (dt, J = 4.7, 8.8 Hz, 1H), 2.92 (td, J = 9.1, 13.5 Hz, 1H), 2.86 - 2.76 (m, 
1H), 2.67 - 2.55 (m, 1H), 1.89 (td, J = 4.4, 13.5 Hz, 1H). 13C NMR (101MHz, CDCl3) δ 
142.69, 139.57, 135.56, 133.46, 128.49, 128.40, 127.22, 126.81, 119.45, 113.95, 113.09, 
101.92, 49.15, 46.02, 41.29, 40.55, 34.76. 
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4-bromo-1-(tert-butyldimethylsilyl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.10): In a 
flame-dried 250 mL three- necked round-bottom flask under argon was added a solution of 
4.70 (1.30 g, 2.78 mmol) in dry toluene (10 mL). To this was added distilled furan (2.0 mL, 
27.8 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyl 
lithium (2.4 mL, 2.60 mmol) in hexanes was added dropwise via syringe over 15 min. The 
solution was stirred at -78 oC for 30 min then allowed to slowly warm to room temperature. 
The reaction was then quenched by addition of saturated NH4Cl (20 mL). After stirring for 5 
minutes, the mixture was diluted with water (20 mL) and extracted with diethyl ether (3 x 20 
mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to give a 
colorless oil that solidifies at cold freezer temperatures 6.10 (0.816 g, 78%), MP: 135.1-136 
oC 1H NMR (400MHz, CDCl3): δ 7.35 (s, 1H), 7.23 (d, J = 3.5 Hz, 1H), 7.15 (dd, J = 5.5, 1.8 
Hz, 1H), 7.11 (dd, J = 5.5, 1.8 Hz, 1H), 6.66 (d, J = 3.5 Hz, 1H), 6.22 (app. t, J = 0.8 Hz, 
1H), 5.79 (dd, J = 1.6, 1.0 Hz, 1H), 1.02 (s, 9H), 0.65 (s, 3H), 0.60 (s, 3H). 13C-NMR: δ 
146.1, 144.8, 142.5, 135.2, 133.3, 132.5, 131.8, 117.1, 110.3, 105.7, 83.0, 82.8, 26.4, 19.3, 
2.1, 2.9.   
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1H NMR (400MHz, cdcl3) δ = 7.35 (s, 1H), 7.23 (d, J=3.5 Hz, 1H), 7.16 (dd, J=1.8, 5.6 Hz, 
1H), 7.11 (dd, J=1.8, 5.6 Hz, 1H), 6.65 (d, J=3.1 Hz, 1H), 6.22 (s, 1H), 5.79 (s, 1H), 1.02 (s, 
9H), 0.64 (s, 3H), 0.60 (s, 3H) 
 
 
 
4-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.11): In a flame-dried 100 mL three- 
necked round-bottom flask under argon was added a solution of 6.10 (0.232 g, 0.620 mmol) 
in dry tetrahydrofuran (8 mL). The solution was cooled to 0 oC for 10 min. To this was added 
1.0 M tetrabutylammonium fluoride (TBAF) (1.25 mL, 1.24 mmol) dropwise. Reaction was 
then followed by TLC and showed completion after 5 min. The reaction was then quenched 
by addition of saturated NH4Cl (10 mL). The reaction was then extracted with diethyl ether 
(2 x 10 mL). The combined organic phase was dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude material was then purified via 
column chromatography on silica gel using 30% dichloromethane in hexanes as eluent to 
give 0.150 g (92%) of 6.11 as a foamy white solid. 1H NMR (400MHz, CDCl3) d = 8.20 (br. 
s., 1H), 7.35 (s, 1H), 7.21 (dd, J = 3.4 Hz, 2.5, 1H), 7.15 (dd, J = 5.4, 1.9 Hz, 1H), 7.07 (dd, J 
= 5.6, 2.0 Hz, 1H), 6.57 (dd, J = 3.2, 2.0 Hz, 1H), 5.99 (dd, J = 1.6, 0.7 Hz, 1H), 5.84 (dd, J = 
1.6, 0.7 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 145.90, 144.66, 142.50, 131.02, 130.02, 
128.06, 125.81, 116.80, 110.22, 103.59, 82.93, 80.52. 
 
  63 
 
1-allyl-4-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.12): In a flame-dried 100 mL 
round-bottom flask under argon was added a solution of 6.11 (250 mg, 0.970 mmol) in dry 
tetrahydrofuran (20 mL). To the solution was added sodium hydride (92.6 mg, 3.86 mmol) 
and catalytic tetrabutylammonium iodide (1.8 mg, 0.005 mmol). The solution was then 
cooled to 0 oC for 10 min. To this was added allyl bromide (0.25 mL, 2.91 mmol) dropwise. 
TLC analysis showed completion after 30 min and therefore the reaction was then quenched 
by addition of saturated NH4Cl (20 mL). The reaction was then extracted with diethyl ether 
(2 x 10 mL). The combined organic phase was dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude material was then purified via 
column chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to 
afford 6.12 as a yellowish oil (261 mg, 90%), MP: 115-116 oC. 1H NMR (400MHz, CDCl3): 
δ = 7.32 (s, 1H), 7.11 (dd, J = 1.8, 5.6 Hz, 1H), 7.06 (d, J = 3.2 Hz, 1H), 7.02 (dd, J = 1.8, 
5.6 Hz, 1H), 6.50 (d, J = 3.2 Hz, 1H), 6.10 - 6.08 (m, 1H), 6.08 - 6.00 (m, 1H), 5.80 (dd, J = 
0.7, 1.9 Hz, 1H), 5.27 - 5.22 (m, 1H), 4.95 (dtd, J = 0.9, 1.9, 17.2 Hz, 1H), 4.90 - 4.82 (m, 
1H), 4.76 - 4.69 (m, 1H). 13C NMR (101MHz, CDCl3): δ 146.01, 144.36, 143.44, 133.55, 
131.13, 130.82, 130.07, 128.72, 117.10, 116.54, 110.47, 102.32, 82.61, 81.28, 50.34. 
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4-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.13): In a flame-
dried 100 mL round-bottom flask under argon was added a solution of 6.11 (126 mg, 0.480 
mmol) in dry tetrahydrofuran (8 mL). To the solution was added sodium hydride (46.1 mg, 
1.92 mmol) and catalytic tetrabutylammonium iodide (8.9 mg, 0.020 mmol). The solution 
was then cooled to 0 oC for 10 min. To this was added homo-allyl bromide (4-bromo-1-
butene) (0.63 mL, 1.44 mmol) dropwise. TLC analysis showed completion after 1 h. The 
reaction was then quenched by addition of saturated NH4Cl (20 mL). The reaction was then 
extracted with diethyl ether (2 x 10 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 50% methyl tert-
butyl ether in hexanes as eluent to afford 6.13  (127 mg, 82%) as a yellowish oil. 1H NMR 
(400MHz, CDCl3): δ 7.33 (s, 1H), 7.16 (dd, 1.8, 5.3 Hz, 1H), 7.12(dd, 1.8, 5.3 Hz,  1H), 7.06 
(d, J = 3.2 Hz, 1H), 6.48 (d, J = 3.2 Hz, 1H), 6.16 (d, J = 0.9 Hz, 1H), 5.83 (d, J = 1.8 Hz, 
1H), 5.82 - 5.72 (m, 1H), 5.15 - 5.08 (m, 2H), 4.25 (td, J = 7.2, 14.3 Hz, 1H, 1H), 4.15 (td, J 
= 7.2, 14.3 Hz, 1H), 2.57 (tq, J = 1.4, 7.1 Hz, 2H). 13C NMR (101MHz, CDCl3): δ 144.67, 
143.71, 143.06, 133.83, 133.04, 131.07, 130.29, 130.04, 119.52, 118.03, 106.45, 101.19, 
83.51, 82.20, 47.64, 35.33. 
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(2S,9aR)-4-bromo-2-vinyl-7,9a-dihydro-2H-1-oxa-6a-azacyclohepta[jkl]-as-indacene 
(1b): In a 25 mL dry sealed tube was added a solution of 6.12 (0.150 g (0.500 mmol) in 
CH2Cl2 (5 mL). The solution was stirred and purged with argon. To the solution was added 
Grubbs’s first generation catalyst (20.6 mg, 0.025 mmol) and refluxed for 0.5 h. TLC 
analysis showed completion of the reaction. The reaction was cooled to r.t. and the ruthenium 
scavenger; tris (hydroxymethyl)-phosphine (0.248 g, 2.00 mmol) dissolved in methanol (2 
mL) and Et3N (0.5 mL) was added to the solution and stirred overnight. H2O (5 mL) was 
then added and stirred vigorously for 0.5 h. With the phases separated, the organic layer was 
washed with brine (5 mL) and dried over anhydrous MgSO4. The solution was then filtered 
and concentrated under reduced pressure to afford a dark brown to black oil. 
Chromatography on silica with 60% dichloromethane in hexanes as eluents afforded 1b 
(0.061 g, 39%) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 7.05 (d, J = 3.2 Hz, 1H), 
7.00 (s, 1H), 6.44 (d, J = 3.2 Hz, 1H), 6.40 - 6.34 (m, 1H), 5.94 - 5.82 (m, 2H), 5.69 (dd, J = 
3.4, 7.8 Hz, 1H), 5.53 - 5.47 (m, 1H), 5.32 (td, J = 1.0, 10.0 Hz, 1H), 5.12 (ddd, J = 2.3, 5.3, 
14.9 Hz, 1H), 4.44 (dd, J = 8.5, 14.9 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 139.47, 
137.38, 134.84, 131.18, 128.45, 128.26, 122.85, 120.25, 118.27, 116.27, 113.80, 101.32, 
86.07, 78.89, 45.25.  
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(2S,10aR,Z)-4-bromo-2-vinyl-2,7,8,10a-tetrahydro-1-oxa-6a-azacycloocta[jkl]-as-
indacene (3b): In a 25 mL dry sealed tube was added a solution of 6.13 (0.100 g (0.320 
mmol) in CH2Cl2 (3 mL). The solution was stirred and purged with argon. To the solution 
was added Grubbs’s first generation catalyst (13.0 mg, 0.016 mmol) and refluxed for 0.5 h. 
TLC analysis showed completion of the reaction. The reaction was cooled to r.t. and the 
ruthenium scavenger; tris (hydroxymethyl)-phosphine (0.159 g, 1.28 mmol) dissolved in 
methanol (1.5 mL) and Et3N (0.5 mL) was added to the solution and stirred overnight. H2O 
(3 mL) was then added and stirred vigorously for 0.5 h. With the phases separated, the 
organic layer was washed with brine (3 mL) and dried over anhydrous MgSO4. The solution 
was then filtered and concentrated under reduced pressure to afford a dark brown to black oil. 
Purification was achieved via silica gel chromatography and 50% dichloromethane in 
hexanes to afford 3b (0.039 g, 39%) as yellowish oil. 1H NMR (400MHz, CDCl3): δ 7.08 (d, 
J = 3.1 Hz, 1H), 7.02 (s, 1H), 6.54 (d, J = 3.1 Hz, 1H), 6.51 (sxt, J = 2.4 Hz, 1H), 5.94 (dq, J 
= 2.4, 5.0, 13.0 Hz 1H), 5.91 - 5.85 (m, 1H), 5.67 (dd, J = 2.0, 7.8 Hz, 1H), 5.52 - 5.42 (m, 
2H), 5.24 (d, J = 9.8 Hz, 1H), 4.47 (ddd, J = 1.6, 12.2, 15.1 Hz, 1H), 4.20 (ddd, J = 2.9, 5.0, 
15.1 Hz, 1H), 2.81 (tddd, J = 2.0, 4.7, 7.1, 19.2 Hz, 1H), 2.59 (qddd, J = 2.4, 4.5, 12.0, 19.1 
Hz, 1H). 13C NMR (101MHz, CDCl3): δ 139.01, 135.23, 134.40, 130.83, 128.96, 128.53, 
125.13, 122.51, 116.79, 116.16, 114.11, 102.39, 85.81, 80.41, 46.13, 34.52.  
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4-bromo-1-(tert-butyldimethylsilyl)-6,9-dimethyl-6,9-dihydro-1H-6,9-
epoxybenzo[g]indole (6.14): In a flame-dried 25 mL round-bottom flask under argon was 
added a solution of 4.70 (0.900 g, 1.92 mmol) in dry toluene (10 mL). To this was added 2,5-
dimethyl furan (2.10 mL, 19.2 mmol). The resulting solution was cooled to -78 oC, then 2.5 
M solution of n-butyl lithium (2.4 mL, 4.23 mmol) in hexanes was added dropwise via 
syringe over 15 min. The solution was stirred at -78 oC for 30 min then allowed to slowly 
warm to room temperature. The reaction was then quenched by addition of saturated NH4Cl 
(20 mL). After stirring for 5 minutes, the mixture was diluted with water (20 mL) and 
extracted with diethyl ether (3 x 20 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 10% methyl tert-
butyl ether in hexanes as eluent to give 6.14 (0.557 g, 72%) as a yellowish oil, MP: 114-115 
oC. 1H NMR (400MHz, CDCl3): δ 7.32 (d, J = 3.5Hz, 1 H); 7.16 (d, J = 5.3 Hz, 1 H); 6.95 
(d, J = 5.3 Hz, 1 H); 6.70 (d, J = 3.5 Hz, 1 H); 2.11 (s, 3 H); 1.92 (s, 3 H); 1.10 (s, 9 H); 0.58 
(s, 3 H); 0.25 (s, 3 H). 13C NMR (101MHz, CDCl3): δ 150.0, 148.0, 145.4, 138.6, 136.6, 
135.2, 132.5, 115.9, 109.8, 107.3, 90.3, 87.4, 27.3, 20.0, 19.2, 15.9, -0.8, -2.0. 
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4-bromo-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.15): In a flame-dried 
100 mL round-bottom flask under argon was added a solution of 6.14 (1.15 g, 2.83 mmol) in 
dry tetrahydrofuran (10 mL). The solution was cooled to 0 oC for 10 min. T8 this was added 
1.0 M tetrabutylammonium fluoride (TBAF) (5.70 mL, 5.65 mmol) dropwise. Reaction was 
then followed by TLC and showed completion after 20 min. The reaction was then quenched 
by addition of saturated NH4Cl (20 mL). The reaction was then extracted with diethyl ether 
(2 x 20 mL). The combined organic phase was dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude material was then purified via 
column chromatography on silica gel using 60% tert-butyl methyl ether in hexanes as eluent 
to give 6.15 (0.72 g, 72%) of as a foamy white solid. 1H-NMR (400 MHz, CDCl3): δ 8.12 
(br. s, 1 H), 7.22 (s, 1 H); 7.20 (dd, J = 3.4, 2.5 Hz, 1 H); 6.88 (m, 2 H); 6.57 (dd, J = 3.5, 2.0 
Hz, 1 H); 2.12 (s, 3 H); 1.94 (s, 3 H). 13C NMR (101 MHz, CDCl3): δ 150.0, 148.2, 146.9, 
134.1, 129.8, 128.3, 126.0, 115.4, 110.0, 103.4, 89.8, 88.5, 16.9, 15.6. 
 
 
 
 1-allyl-4-bromo-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.16): In a 
flame-dried 100 mL round-bottom flask under argon was added a solution of 6.15 (140 mg, 
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0.484 mmol) in dry tetrahydrofuran (10 mL). To the solution was added sodium hydride 
(47.0 mg, 1.94 mmol) and catalytic tetrabutylammonium iodide (0.90 mg, 0.002 mmol). The 
solution was then cooled to 0 oC for 10 min. To this was added allyl bromide (0.13 mL, 1.45 
mmol) dropwise. TLC analysis showed completion after 30 min. The reaction was then 
quenched by addition of saturated NH4Cl (10 mL). The reaction was then extracted with 
diethyl ether (2 x 10 mL). The combined organic phase was dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was 
then purified via column chromatography on silica gel using 40% methyl tert-butyl ether in 
hexanes as eluent to afford 6.16 (111 mg, 78%) as a yellowish oil. 1H-NMR (400 MHz, 
CDCl3): δ 7.19 (s, 1 H); 7.03 (d, J = 3.2 Hz, 1 H); 6.81 (dd, J = 5.3, 19.3 Hz, 2 H); 6.54 (d, J 
= 3.5 Hz, 1 H); 6.01 (tdd, J = 4.1, 10.5, 17.1 Hz, 1H); 5.21 - 5.16 (m, 1H); 4.98 - 4.91 (m, 
1H); 4.80 - 4.73 (m, 2H); 2.15 (s, 3 H); 1.93 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 151.0, 
148.3, 147.2, 134.8, 134.0, 131.7, 131.0, 129.6, 116.6, 115.0, 110.7, 102.8, 90.2, 88.6, 51.3, 
20.3, 15.5.  
 
 
 
 
4-bromo-1-(but-3-en-1-yl)-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.17): 
In a flame-dried 100 mL round-bottom flask under argon was added a solution of 6.15 (214 
mg, 0.740 mmol) in dry tetrahydrofuran (8 mL). To the solution was added sodium hydride 
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(71.0 mg, 2.96 mmol) and catalytic tetrabutylammonium iodide (1.40 mg, 0.004 mmol). The 
solution was then cooled to 0 oC for 10 min. To this was added homo-allyl bromide (4-
bromo-1-butene) (0.23 mL, 2.22 mmol) dropwise. TLC analysis showed completion after 
1hr. The reaction was then quenched by addition of saturated NH4Cl (10 mL). The reaction 
was then extracted with diethyl ether (2 x 5 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 5% methyl tert-
butyl ether in hexanes as eluent to afford 6.17 (178 mg, 70%) as a yellowish oil. 1H NMR 
(400MHz, CDCl3): δ 7.19 (s, 1H), 7.04 (d, J = 3.2 Hz, 1H), 6.90 (dd, J = 5.3, 7.6 Hz, 2H), 
6.50 (d, J = 3.5 Hz, 1H), 5.73 (tdd, J = 6.6, 10.4, 17.1 Hz, 1H), 5.12 - 5.03 (m, 2H), 4.43 
(ddd, J = 5.9, 8.2, 14.3 Hz, 1H), 4.19 - 4.10 (m, 1H), 2.53 - 2.41 (m, 2H), 2.18 (s, 3H), 1.94 
(s, 3H). 13C NMR (101 MHz, CDCl3): δ 150.6, 148.8, 146.8, 134.7, 133.7, 130.8, 129.7, 
117.9, 115.0, 110.8, 102.5, 90.2, 88.7, 53.4, 48.6, 35.5, 20.4, 15.6. 
 
 
	  
 
(2S,9aR)-4-bromo-2,9a-dimethyl-2-vinyl-7,9a-dihydro-2H-1-oxa-6a-azacyclohepta[jkl]-
as-indacene (1c): In a 25 mL dry sealed tube was added a solution of 6.16 (0.120 g 0.360 
mmol) in CH2Cl2 (5 mL). The solution was stirred and purged with argon. To the solution 
was added Grubbs’s first generation catalyst (14.8 mg, 0.018 mmol) and refluxed for 0.5 h. 
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TLC analysis showed completion of the reaction. The reaction was cooled to r.t. and the 
ruthenium scavenger; tris (hydroxymethyl)-phosphine (0.178 g, 1.44 mmol) dissolved in 
methanol (1.5 mL) and Et3N (0.3 mL) was added to the solution and stirred overnight. H2O 
(5 mL) was then added and stirred vigorously for 0.5 h. With the phases separated, the 
organic layer was washed with brine (5 mL) and dried over anhydrous MgSO4. The solution 
was then filtered and concentrated under reduced pressure to afford a dark brown to black oil. 
Chromatography on silica gel with 60% dichloromethane in hexanes as eluents afforded 1c 
(0.046 g, 38%) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 7.04 (d, J = 2.92 Hz, 1H), 
6.95 (s, 1H), 6.54 (dd, J = 3.2, 11.7 Hz, 1H), 6.48 (d, J = 2.9 Hz, 1H), 5.98 (ddd, J = 0.9, 
10.5, 17.3 Hz, 1H), 5.70 - 5.62 (m, 1H), 5.34 (apparent t, J = 1.2 Hz, 1H), 5.34 - 5.29 (m, 
1H), 5.22 - 5.14 (m, 1H), 5.06 (td, J = 1.3, 10.6 Hz, 1H), 4.49 (dd, J = 8.9, 15.4 Hz, 1H), 1.89 
(s, 3H), 1.78 (s, 3H). 13C NMR (101MHz, CDCl3): δ  144.7, 143.2, 138.2, 128.5, 128.52, 
128.48, 125.7, 117.7, 116.0, 114.1, 112.6, 101.8, 88.2, 84.3, 45.3, 30.6, 27.7. 
 
 
 
(2S,10aR,Z)-4-bromo-2,10a-dimethyl-2-vinyl-2,7,8,10a-tetrahydro-1-oxa-6a-
azacycloocta[jkl]-as-indacene (3c): In a 25 mL dry sealed tube was added a solution of 6.17 
(0.108 g 0.315 mmol) in CH2Cl2 (5 mL). The solution was stirred and purged with argon. To 
the solution was added Grubbs’ first generation catalyst (13.0 mg, 0.016 mmol) and refluxed 
for 0.5 h. TLC analysis showed completion of the reaction. The reaction was cooled to r.t. 
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and the ruthenium scavenger; tris (hydroxymethyl)-phosphine (0.156 g, 1.26 mmol) 
dissolved in methanol (1.5 mL) and Et3N (0.3 mL) was added to the solution and stirred 
overnight. H2O (5 mL) was then added and stirred vigorously for 0.5 h. With the phases 
separated, the organic layer was washed with brine (5 mL) and dried over anhydrous 
MgSO4. The solution was then filtered and concentrated under reduced pressure to afford a 
dark brown to black oil. Chromatography on silica with 60% dichloromethane in hexanes as 
eluents afforded 3c (0.044 g, 41%) as a yellow oil. 1H NMR (400MHz, CDCl3): δ 7.08 (d, J 
= 3.6 Hz, 1H), 7.01 (s, 1H), 6.57 (d, J = 3.0 Hz, 1H), 6.20 - 6.13 (m, 1H), 6.04 (dd, J = 10.5, 
17.0 Hz, 1H), 5.44 (ddd, J = 3.1, 6.5, 13.3 Hz, 1H), 5.34 - 5.26 (m, 1H), 5.04 (dd, J = 1.5, 
10.5 Hz, 1H), 4.58 (ddd, J = 1.3, 11.2, 15.3 Hz, 1H), 4.26 (ddd, J = 2.3, 6.4, 15.3 Hz, 1H), 
2.83 - 2.71 (m, 1H), 2.32 - 2.32 (m, 1H), 2.37 (qdd, J = 2.7, 11.2, 19.3 Hz, 1H), 1.93 (s, 3H), 
1.68 (s, 3H). 13C NMR (101MHz, CDCl3): δ 143.71, 140.50, 137.97, 130.06, 129.71, 129.66, 
124.24, 123.69, 116.33, 114.39, 112.18, 102.33, 86.69, 85.92, 53.42, 47.01, 36.02, 33.58, 
28.33. 
 
 
6.4: Alternative Syntheses 
 
 
1-allyl-4,6,7-tribromo-1H-indole (3.41): In a flame-dried 100 mL round-bottom flask under 
argon was added a solution of 3.4 (2.00 g, 5.65 mmol) in dry tetrahydrofuran (30 mL). To the 
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solution was added sodium hydride (0.900 g, 22.6 mmol) and catalytic tetrabutylammonium 
iodide (11.1 mg, 0.030 mmol). The solution was then cooled to 0 oC for 10 min. To this was 
added allyl bromide (1.50 mL, 16.95 mmol) dropwise. TLC analysis showed completion 
after 30 min. The reaction was then quenched by addition of saturated NH4Cl (60 mL). The 
reaction was then extracted with diethyl ether (3 x 60 mL). The combined organic phase was 
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude material was then purified via column chromatography on silica gel using 5% 
methyl tert-butyl ether in hexanes as eluent to afford 3.41  (2.11 g, 95.0%) as granular white 
solid. 1H NMR (400MHz, cdcl3) δ 7.56 (s, 1H), 7.11 (d, J = 3.2 Hz, 1H), 6.56 (dd, J = 1.8, 
3.2 Hz, 1H), 6.10 - 5.99 (m, 1H), 5.20 - 5.13 (m, 3H), 4.7 (d, J = 17.1 Hz 1H). 13C NMR (101 
MHz, CDCl3): δ 134.4, 133.4, 132.2, 130.8, 126.9, 119.6, 116.6, 114.4, 105.9, 102.8, 51.0, 
31.6, 22.6, 14.1. 
 
 
 
 
 
4,6,7-tribromo-1-(but-3-en-1-yl)-1H-indole (3.42): In a flame-dried 100 mL round-bottom 
flask under argon was added a solution of 3.4 (720 mg, 2.03 mmol) in dry tetrahydrofuran 
(10 mL). To the solution was added sodium hydride (326 mg, 8.14 mmol) and catalytic 
tetrabutylammonium iodide (3.80 mg, 0.010 mmol). The solution was then cooled to 0 oC for 
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10 min. To this was added homo-allyl bromide (4-bromo-1-butene) (0.60 mL, 6.10 mmol) 
dropwise. The reaction was monitored by TLC analysis which showed starting material even 
after 4 h. The reaction was then quenched by addition of saturated NH4Cl (10 mL). The 
reaction was then extracted with diethyl ether (2 x 5 mL). The combined organic phase was 
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude material was then purified via column chromatography on silica gel using 5% 
methyl tert-butyl ether in hexanes as eluent to afford 3.42 (372.6 mg, 45.0%) as a yellowish 
oil and unreacted starting material (70% yield based on starting material recovered). 1H NMR 
(400MHz, cdcl3) δ 7.55 (s, 1H), 7.09 - 7.06 (m, 1H), 6.51 - 6.49 (m, 1H), 5.83 - 5.70 (m, 1H), 
5.07 (d, J = 12.9 Hz, 2H), 4.61 - 4.53 (m, 2H), 2.58 (d, J = 6.7 Hz, 2H). 13C NMR (101MHz, 
CHLOROFORM-d) d = 133.7, 133.2, 132.3, 131.0, 126.7, 119.4, 117.9, 114.4, 105.7, 102.3, 
48.6, 36.7. 
 
 
 
 
1-allyl-4-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (3.44): In a flame-dried 
1000 mL three- necked round-bottom flask under argon was added a solution of 3.41 (100 
mg, 0.25 mmol) in dry toluene (8 mL). To this was added cyclopentadiene (0.2 mL, 2.5 
mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyllithium 
(0.20 mL, 0.51 mmol) in hexanes was added dropwise via syringe over 15 min. The solution 
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was stirred at -78oC for 30 min then allowed to slowly warm to room temperature. The 
reaction was then quenched by addition of saturated NH4Cl (8 mL). After stirring for 5 
minutes, the mixture was diluted with water (8 mL) and extracted with diethyl ether (3 x 8 
mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to give 
3.44 (60 mg, 80%) as yellowish oil that solidifies at cold freezer temperatures.  
 
 
 
 
4-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (3.46): In a flame-
dried 100 mL three- necked round-bottom flask under argon was added a solution of 3.42 
(100 mg, 0.245 mmol) in dry toluene (10 mL). To this was added cyclopentadiene (0.20 mL, 
2.45 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (0.22 mL, 0.54 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (10 mL). After 
stirring for 5 minutes, the mixture was diluted with water (20 mL) and extracted with diethyl 
ether (3 x 10 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
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purified via column chromatography on silica gel using 5% methyl tert-butyl ether in 
hexanes as eluent to give 3.46 (45 mg, 59%) as clear oil that solidified at cold freezer 
temperatures.  
 
 
 
1-allyl-4-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.12): In a flame-dried 
250 mL three- necked round-bottom flask under argon was added a solution of 3.41 (1.07 g, 
2.72 mmol) in dry toluene (10 mL). To this was added distilled furan (2.0 mL, 27.2 mmol). 
The resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyllithium (2.2 mL, 
5.44 mmol) in hexanes was added dropwise via syringe over 15 min. The solution was stirred 
at -78oC for 30 min then allowed to slowly warm to room temperature. The reaction was then 
quenched by addition of saturated NH4Cl (20 mL). After stirring for 5 minutes, the mixture 
was diluted with water (20 mL) and extracted with diethyl ether (3 x 20 mL). The combined 
organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under 
reduced pressure. The crude material was then purified via column chromatography on silica 
gel using 5% methyl tert-butyl ether in hexanes as eluent to give 6.12 (0.816 g, 78%) as 
colorless oil that solidifies at cold freezer temperatures.  
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4-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.13): In a flame-
dried 250 mL three- necked round-bottom flask under argon was added a solution of 3.42 
(200 mg, 0.490 mmol) in dry toluene (10 mL). To this was added distilled furan (3.60 mL, 
49.0 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (0.40 mL, 0.490 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78 oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (20 mL). After 
stirring for 5 minutes, the mixture was diluted with water (20 mL) and extracted with diethyl 
ether (3 x 20 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
purified via column chromatography on silica gel using 5% methyl tert-butyl ether in 
hexanes as eluent to give 6.13 (0.96 g, 62%) as colorless oil that solidifies at cold freezer 
temperatures. 
 
 
1-allyl-4-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.16): In a flame-dried 
250 mL three- necked round-bottom flask under argon was added a solution of 3.41 (430 mg, 
1.10 mmol) in dry toluene (11 mL). To this was added 2,5-dimethyl furan (1.20 mL, 10.9 
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mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyllithium 
(0.9 mL, 2.2 mmol) in hexanes was added dropwise via syringe over 15 min. The solution 
was stirred at -78oC for 30 min then allowed to slowly warm to room temperature. The 
reaction was then quenched by addition of saturated NH4Cl (10 mL). After stirring for 5 
minutes, the mixture was diluted with water (10 mL) and extracted with diethyl ether (3 x 10 
mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to give 
6.16 (0.28 g, 77%) as yellow oil.  
 
 
 
4-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.17): In a flame-
dried 10 mL three- necked round-bottom flask under argon was added a solution of 3.42 (48 
mg, 0.12 mmol) in dry toluene (5 mL). To this was added 2,5-dimethyl furan (0.13 mL, 1.18 
mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyllithium 
(0.10 mL, 0.26 mmol) in hexanes was added dropwise via syringe over 15 min. The solution 
was stirred at -78oC for 30 min then allowed to slowly warm to room temperature. The 
reaction was then quenched by addition of saturated NH4Cl (5 mL). After stirring for 5 
minutes, the mixture was diluted with water (5 mL) and extracted with diethyl ether (3 x 5 
mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
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concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to give 
6.17 (0.028 g, 68%) as yellow oil.  
 
 
6.4: 5,6,7-Tribromoindole via Bartoli Route 
 
 
 
1,2,3-Tribromobenzene (4.82): In a 500-mL round-bottom flask was dissolved 5.78 g (25.9 
mmol) of CuBr2 in 200 mL of dry CH3CN and the mixture heated to 60 °C. To this warm 
solution was added 3.80 mL (31.9 mmol) tert-butyl nitrite, followed by a solution of 5.01 g 
(19.9 mmol) of commercially available 2,6-dibromoaniline 4.81 in 50 mL CH3CN. The 
mixture was stirred at 60 °C for 1 h, then cooled to room temperature and poured into 200 
mL 20% aqueous ammonia. The mixture was extracted with hexane (2 x 200 mL) and the 
combined organic phase was washed sequentially with 20% aqueous ammonia (100 mL), 
water (100 mL), brine (50 mL), and then dried over anhydrous magnesium sulfate. The 
contents were filtered and concentrated under reduced pressure. The resulting crude material 
was recrystallized from ethanol to give 5.12 g (80%) of 1,2,3-tribromobenzene 4.82 as an 
off-white solid, MP: 88-90 °C. 1H NMR (CDCl3): δ 7.58 (d, J = 8.0 Hz, 2 H), 7.03 (t, J = 8.0 
Hz, 1 H); 13C NMR (CDCl3): δ 132.6, 129.2, 127.7, 126.2. The physical and spectral data is 
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consistent with that which was previously reported for this compound (Menzel, Fisher et al., 
2006; Teclechiel, Sundstroem et al., 2009). 
 
 
1,2,3-Tribromo-4-nitrobenzene (4.83): In a 250-mL round-bottom flask was dissolved 5.00 
g (15.9 mmol) of 4.82 in 100 mL of 1,2-dichloroethane and the mixture cooled to 0 °C. To 
the vigorously stirred solution at 0 °C was added 7.00 mL (159 mmol) of fuming HNO3 
dropwise over 15 minutes. The mixture was stirred at 0 °C for 1 h and then poured over 500 
mL of ice. After 30 minutes, 100 mL of CH2Cl2 was added and the organic layers extracted 
with water (3 x 100 mL), saturated NaHCO3 (3 x 100 mL), brine (100 mL), and then dried 
over anhydrous magnesium sulfate. The contents were filtered and concentrated under 
reduced pressure. The crude material was recrystallized from hexanes to give 4.74 g (82%) of 
2,3,4-tribromonitrobenzene 4.83 as an off-white solid: MP: 82-84 °C. 1H NMR (CDCl3): 
δ 7.76 (d, J = 8.6 Hz, 1 H), 7.51 (d, J = 8.6 Hz, 1 H); 13C NMR (101 MHz CDCl3): δ 132.6, 
132.5, 131.1, 130.1, 123.7, 118.7; HRMS (EI) m/e calcd for C6H2Br3NO2 356.7635, found 
356.7633. This compound has been reported in the literature, but no spectral or physical data 
except melting point was given (Chen, Konstantinov et al., 2001). 
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5,6,7-Tribromoindole (4.84) via Bartoli route: In 250-mL round-bottom flask was 
dissolved 2.01 g (5.55 mmol) of 4.83 in 20 mL of dry THF and cooled to -40 °C.  To the 
vigorously stirred solution was added 16.7 mL (16.7 mmol) of 1 M vinyl magnesium 
bromide via syringe at once. The mixture was stirred for 1 h. The mixture was quenched with 
100 mL saturated NH4Cl and then extracted with diethyl ether (2 x 100 mL) and the 
combined organic phase was washed sequentially with water (100 mL), brine (50 mL), and 
dried over anhydrous magnesium sulfate. The material was filtered and concentrated under 
reduced pressure. The crude material was then purified via flash column chromatography on 
silica gel using 10% EtOAc (ethyl acetate) in hexanes as the eluent to give 0.628 g (32%) of 
4.84 as a white solid, MP: 132-134 °C. 1H-NMR (400 MHz, CDCl3): δ  8.36 (bs, 1 H, NH); 
7.89 (s, 1 H); 7.27 (dd, J = 3.3, 3.3 Hz, 1 H); 6.57 (dd, J = 3.3, 3.3 Hz, 1 H). 13C NMR (101 
MHz, CDCl3): δ 134.8, 128.2, 126.4, 124.0, 119.2, 115.5, 107.9, 103.5; HRMS (EI) m/e 
calcd for C8H4Br3N 350.7893, found 350.7891. This compound was reported in the literature, 
but no spectral data was provided: (Ohta, T and Somei, 1989). 
 
 
 
2,6-Dibromo-4-methylaniline (6.19): In 500-mL round-bottom flask was dissolved 10.7 g 
(100 mmol) 6.18 in 300 mL of dry methanol. To the vigorously stirred solution was carefully 
added 50.6 mL (300 mmol) concentrated aqueous HBr (47% wt/wt) followed by 22.7 mL 
(200 mmol) 30% aqueous H2O2 dropwise over 15 minutes. The mixture was stirred 
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overnight. The mixture was poured into 1.0 L of 1 M NaOH and the resulting suspension was 
filtered and washed with water until neutral. Dried under vacuum at 50 °C gave 26.2 g (99%) 
of 6.19 as a purple amorphous solid, MP: 74-76 °C. Physical properties were identical to that 
of the commercially available compound. 
 
 
 
3,4,5-Tribromotoluene (6.20): In a 1-L round-bottom flask was dissolved 11.6 g (52.0 
mmol) CuBr2 in 300 mL of dry CH3CN and heated to 60 °C. To the warm solution was added 
7.6 mL (64 mmol) tert-butyl nitrite followed by a solution of 10.6 g (40.0 mmol) of 6.19 in 
100 mL of CH3CN. The mixture was stirred at 60 °C for 1 h. The solution was cooled to 
room temperature and poured into 400 mL of 20% aqueous ammonia. The mixture was 
extracted with hexane (2 x 400 mL) and the combined organic layers were washed 
sequentially with 20% aqueous ammonia (200 mL), water (200 mL), brine (100 mL), and 
then dried over anhydrous magnesium sulfate. The solution was filtered and concentrated 
under reduced pressure. The crude material was recrystallized from ethanol to give 11.3 g 
(80%) of 6.20 as off-white needles, MP: 92-94 °C. 1H-NMR (400 MHz, CDCl3): δ  7.38 (s, 2 
H), 2.24 (s, 3 H); 13C NMR (101 MHz, CDCl3): δ 139.4, 133.0, 125.4, 123.8, 20.4. This 
compound was consistent with the melting point and 1H NMR values previously reported 
(Doyle, Van Lente, et al., 1980) 
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1,2,3-Tribromo-5-methyl-4-nitrobenzene (6.21): In a 250-mL round-bottom flask was 
dissolved 10.0 g (30.9 mmol) of 6.20 in 100 mL of 1,2-dichloroethane and cooled to 0 °C. To 
the vigorously stirred solution at 0 °C was added 13.5 mL (309 mmol) of fuming HNO3 
dropwise over 15 minutes. The mixture was stirred at 0 °C for 1 h and then poured into 500 
mL of ice. After 30 minutes 100 mL of CH2Cl2 was added and extracted.  The organic layer 
was washed sequentially with water (3 x 200 mL), saturated NaHCO3 (3 x 100 mL), brine 
(100 mL), dried over anhydrous magnesium sulfate. The solution was filtered and 
concentrated under reduced pressure. The crude material was recrystallized from hexanes to 
give 9.46 g (82%) of 6.21 as off-white solid, MP: 106-108 °C. 1H NMR (400 MHz, CDCl3): 
δ 7.58 (s, 1 H), 2.26 (s, 3 H); 13C NMR (101 MHz, CDCl3): δ 151.6, 134.4, 130.8, 127.3, 
126.7, 117.0, 17.1; HRMS (EI) m/e calcd for C7H4Br3NO2 370.7791, found 370.7790.  
 
 
 
5,6,7-Tribromoindole (4.84) via Leimgruber-Batcho route: In a 50-mL round-bottom 
flask a mixture of 6.52 g (17.4 mmol) 6.21 and 6.92 g (26.1 mmol) TPM was heated to 105 
°C under water-aspirator vacuum with vigorous stirring. After 3 h an aliquot of the mixture 
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showed complete reaction by TLC (20% dichloromethane in hexane). Cooled to room 
temperature and passed through a plug of silica gel eluting with 50% tert-butyl methyl ether 
in hexanes and concentrated under reduced pressure to give 8.15 g of crude intermediate 
which was then suspended in 150 mL methanol in a 250 mL round-bottom flask and heated 
to reflux. To the red solution was added 0.305 g (1.13 mmol) FeCl3•6H2O and 0.689 g (57.4 
mmol) activated carbon. The mixture was refluxed for 5 minutes, and then 3.35 mL (68.7 
mmol) NH2NH2•H2O was added via a syringe over 10 minutes and refluxed for 1 h. The 
mixture was cooled to room temperature and filtered through a 1-cm pad of Celite, washing 
with methanol. The filtrate was concentrated under reduced pressure to about 5 mL, then 
diluted with 1M HCl (250 mL), extracted with CH2Cl2 (3 x 75 mL). The combined organic 
phases were washed with water (2 x 100 mL), brine (50 mL), and dried over anhydrous 
magnesium sulfate. The solution was filtered and concentrated under reduced pressure. The 
crude material was then purified via column chromatography on silica gel using 10% CH2Cl2 
in hexanes as eluent to give 3.68 g (61%) of 4.84 as a white solid, MP: 132-134 °C. 1H-NMR 
(400 MHz, CDCl3): δ  8.36 (br. s, 1 H, NH); 7.89 (s, 1 H); 7.27 (dd, J = 3.3, 3.3 Hz, 1 H); 
6.57 (dd, J = 3.3, 3.3 Hz, 1 H). 13C NMR (101 MHz, CDCl3): δ 134.8, 128.2, 126.4, 124.0, 
119.2, 115.5, 107.9, 103.5. HRMS (EI) m/e calcd for C8H4Br3N 350.7893, found 350.7891.  
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5,6,7-Tribromo-1-(tert-butyldimethylsilyl)-1H-indole (6.22): In a flame-dried 250-mL 
three-neck round bottom flask under argon was added a solution of 1.00 g (2.82 mmol) 4.84 
in 50 mL dry THF. To this was added 0.271 g (11.3 mmol) of NaH followed by 0.80 mL (5.6 
mmol) Et3N. The resulting suspension was cooled to 0 °C for 15 min and then 0.92 mL (5.6 
mmol) of tert-butyldimethylsilyl trifluoromethanesulfonate diluted in 5 mL pentane was 
added dropwise via syringe over 5 min. The solution was stirred at 0 °C for an additional 20 
min. The reaction was then diluted with diethyl ether (50 mL) and quenched by addition of 
saturated NH4Cl (100 mL). Then the mixture was extracted with diethyl ether (3 x 100 mL). 
The combined organic layers were dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 1% TBME in hexanes as the eluent to give 1.03 g (78%) 
of 6.22 as a colorless oil which solidified to a glass at room temperature. 1H-NMR (400 
MHz, CDCl3): δ 7.85 (s, 1 H), 7.41 (d, J = 3.3 Hz, 1 H), 6.57 (d, J = 3.3 Hz, 1 H), 0.97 (s, 9 
H), 0.72 (s, 6 H); 13C NMR (101 MHz, CDCl3): δ 140.5, 136.2, 133.8, 123.7, 121.3, 116.3, 
109.7, 105.0, 27.4, 19.9, 2.2; HRMS (EI) m/e calcd for C14H18Br3NSi 464.8758, found 
464.8755. 
 
 
 
 
5-Bromo-1-(tert-butyldimethylsilyl)-6,9-dihydro-1H-6,9-methanobenzo[g]indole (6.23): 
In a flame-dried 250 mL three- necked round-bottom flask under argon was added a solution 
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of 0.610 g (1.30 mmol) 6.22 in 60 mL dry toluene. To this was added 1.72 g (26.0 mmol) of 
freshly cracked cyclopentadiene. The resulting solution was cooled to -78 °C, then 1.04 mL 
(2.60 mmol) of a 2.5 M solution of n-butyllithium in hexanes was added dropwise via 
syringe over 15 min. The solution was stirred at -78 °C for 30 min then allowed to slowly 
warm to room temperature. The reaction was then quenched by addition of saturated NH4Cl 
(50 mL). After stirring for 5 minutes, the mixture was diluted with water (100 mL) and 
extracted with diethyl ether (3 x 100 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 1% methyl tert-
butyl ether in hexanes as eluent to give 0.35 g (72%) of 6.23 as a colorless liquid which 
solidifies to a glass below room temperature. 1H NMR (400 MHz, CDCl3): δ 7.37 (s, 1 H); 
7.16 (d, J = 3.5 Hz, 1 H); 6.98 (dd, J = 5.3, 5.3 Hz, 1 H); 6.85 (dd, J = 5.3, 5.3 Hz, 1 H); 6.48 
(d, J = 3.3 Hz, 1 H); 4.58 (bs, 1 H); 4.26 (bs, 1 H); 2.30 (m, 2 H); 1.20 (s, 9 H); 0.67 (s, 3 H); 
0.59 (s, 3 H). 13C NMR (101 MHz, CDCl3): δ 145.9, 144.7, 142.3, 136.8, 136.0, 133.2, 
133.1, 118.6, 109.6, 104.4, 69.8, 52.0, 51.8, 26.6, 19.4, -1.5, -1.8. HRMS (EI) m/e calcd for 
C19H24BrNSi 373.0862, found 373.0864.  
 
 
 
5-bromo-6,9-dihydro-1H-6,9-methanobenzo[g]indole (6.24). In a flame-dried 100 mL 
three- necked round-bottom flask under argon was added a solution of 6.23 (0.170 g, 0.460 
mmol) in 5 mL dry Tetrahydrofuran (THF). The solution was cooled to 0 oC for 10 min. To 
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this was added 1.0 M tetrabutylammonium fluoride (TBAF) (0.92 mL 0.92 mmol) dropwise. 
Reaction was then followed by TLC and showed completion after 5 min. The reaction was 
then quenched by addition of saturated NH4Cl (5 mL). The reaction was then extracted with 
diethyl ether (2 x 5 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
purified via column chromatography on silica gel using 30% dichloromethane in hexanes as 
eluent to give 0.116 g (97%) of 6.24 as a foamy white solid, MP: 117-120 oC.  1H NMR 
(400MHz, CDCl3) = 7.94 (br. s., 1H), 7.38 (s, 1H), 7.17 - 7.14 (apparent t, J = 2.7 Hz, 1H), 
6.97 (td, J = 2.1, 4.8 Hz, 1H), 6.88 - 6.84 (m, 1H), 6.44 (td, J = 1.3, 2.9 Hz, 1H), 4.28 - 4.23 
(m, 2H), 2.38 (s, 2H). 13C NMR (101 MHz, CDCl3): δ 145.67, 144.44, 142.25, 135.44, 
130.73, 128.81, 125.28, 118.25, 108.96, 102.50, 71.13, 51.60, 48.80. 
 
 
 
1-allyl-5-bromo-6,9-dihydro-1H-6,9-methanobenzo[g]indole (5.64): In a flame-dried 100 
mL round-bottom flask under argon was added a solution of 6.24 (250 mg, 0.970 mmol) in 
dry tetrahydrofuran (20 mL). To the solution was added sodium hydride (92.6 mg, 3.86 
mmol) and catalytic tetrabutylammonium iodide (1.8 mg, 0.005 mmol). The solution was 
then cooled to 0 oC for 10 min. To this was added allyl bromide (0.25 mL, 2.91 mmol) 
dropwise. TLC analysis showed completion after 30 min. The reaction was then quenched by 
addition of saturated NH4Cl (20 mL). The reaction was then extracted with diethyl ether (2 x 
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10 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered 
and concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to afford 
5.64  (261 mg, 90%) as a yellowish oil that solidifies upon cooling, MP: 34-37 oC. 1H NMR 
(400MHz, CDCl3): δ 7.29 (s, 1H), 7.01 (d, J = 3.2 Hz, 1H), 6.89 (ddd, J = 2.9, 5.1, 18.0 Hz, 
2 H), 6.44 (d, J = 3.2 Hz, 1H), 5.80 (tdd, J = 6.8, 10.2, 17.1 Hz, 1H), 5.15 - 5.06 (m, 2H), 
4.38 (br. s, 1H), 4.37 - 4.20 (m, 2H), 4.00 (br. s, 1H), 2.57 (tq, J = 1.4, 7.1 Hz, 2H), 2.38 (ddt, 
J = 1.7, 6.7, 17.8 Hz 1H). 13C NMR (101 MHz, CDCl3): δ 145.94, 144.29, 143.13, 135.22, 
134.12, 131.29, 129.95, 129.94, 129.86, 118.60, 116.45, 108.92, 101.04, 70.68, 51.27, 50.09, 
49.71.  
 
 
5-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-methanobenzo[g]indole (5.66): In a 
flame-dried 100 mL round-bottom flask under argon was added a solution of 6.24 (250 mg, 
0.970 mmol) in dry tetrahydrofuran (20 mL). To the solution was added sodium hydride 
(92.6 mg, 3.86 mmol) and catalytic tetrabutylammonium iodide (1.8 mg, 0.005 mmol). The 
solution was then cooled to 0 oC for 10 min. To this was added homo-allyl bromide (4-
bromo-1-butene) (0.30 mL, 2.91 mmol) dropwise. TLC analysis showed completion after 1 
h. The reaction was then quenched by addition of saturated NH4Cl (20 mL). The reaction was 
then extracted with diethyl ether (2 x 10 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
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material was then purified via column chromatography on silica gel using 5% methyl tert-
butyl ether in hexanes as eluent to afford 5.66  (249 mg,2%) as a yellowish oil. 1H NMR 
(400MHz, CDCl3) δ = 7.38 (s, 1H), 7.02 (dd, J = 3.1, 5.4 Hz, 1H), 6.97 (d, J = 3.2 Hz, 1H), 
6.93 (dd, J =  2.9, 5.3 Hz, 1H), 6.35 (d, J = 3.2 Hz, 1H), 5.81 (tdd, J = 6.8, 10.3, 17.1 Hz, 
1H), 5.17 - 5.08 (m, 2H), 4.51 (br. s, 1H), 4.39 - 4.21 (m, 3H), 2.58 (q, J = 7.0 Hz, 2H), 2.42 
(m,  2H). 
 
	  
(2S,9aR)-3-bromo-2-vinyl-1,2,7,9a-tetrahydro-6a-azacyclohepta[jkl]-as-indacene (2a): 
In a 25 mL dry sealed tube was added a solution of 5.64 (0.150 g (0.500 mmol) in CH2Cl2 (5 
mL). The solution was stirred and purged with argon. To the solution was added Grubbs’ 
first generation catalyst (20.6 mg, 0.025 mmol) and refluxed for 0.5 h. TLC analysis showed 
completion of the reaction. The reaction was cooled to r.t. and the ruthenium scavenger; tris 
(hydroxymethyl)-phosphine (0.248 g, 2.00 mmol) dissolved in methanol (2 mL) and Et3N 
(0.5 mL) was added to the solution and stirred overnight. H2O (5 mL) was then added and 
stirred vigorously for 0.5 h. With the phases separated, the organic layer was washed with 
brine (5 mL) and dried over anhydrous MgSO4. The solution was then filtered and 
concentrated under reduced pressure to afford a dark brown to black oil. Flash 
chromatography was achieved using silica gel and eluting with 40% tert-butyl methyl ether 
in hexanes to give 2a (0.065 g, 43%) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 7.57 
(s, 1H), 6.95 (d, J = 3.2 Hz, 1H), 6.32 (d, J = 2.9 Hz, 1H), 6.11 (dt, J = 2.6, 10.7 Hz, 1H), 
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6.05 - 5.95 (m, 2H), 5.25 - 5.19 (m, 1H), 5.18 - 5.10 (m, 2H), 4.52 (t, J = 9.2 Hz, 1H), 4.39 
(dd, J = 8.2, 14.9 Hz, 1H), 4.00 (q, J = 8.4 Hz, 1H), 2.74 (td, J = 8.0, 12.7 Hz, 1H), 1.80 (td, 
J = 9.9, 12.7 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 141.91, 140.32, 134.56, 133.32, 
129.71, 128.83, 128.59, 123.52, 123.00, 114.94, 111.28, 99.78, 50.55, 45.72, 41.17, 40.82. 
 
 
 
(2S,10aR,Z)-3-bromo-2-vinyl-2,7,8,10a-tetrahydro-1H-6a-azacycloocta[jkl]-as-indacene 
(4a): In a 25 mL dry sealed tube was added a solution of 5.66 (0.145 g (0.460 mmol) in 
CH2Cl2 (10 mL). The solution was stirred and purged with argon. To the solution was added 
Grubbs’ first generation catalyst (19.0 mg, 0.020 mmol) and refluxed for 0.5 h. TLC analysis 
showed completion of the reaction. The reaction was cooled to r.t. and the ruthenium 
scavenger; tris (hydroxymethyl)-phosphine (0.199 g, 1.60 mmol) dissolved in methanol (2 
mL) and Et3N (0.5 mL) was added to the solution and stirred overnight. H2O (5 mL) was 
then added and stirred vigorously for 0.5 h. With the phases separated, the organic layer was 
washed with brine (5 mL) and dried over anhydrous MgSO4. The solution was then filtered 
and concentrated under reduced pressure to afford a dark brown to black oil. Flash 
chromatography was achieved using silica gel and eluting with 5% tert-butyl methyl ether in 
hexanes to give 4a (0.058 g, 40%) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 7.59 (s, 
1H), 6.98 (d, J = 2.9 Hz, 1H), 6.39 (s, 1H), 6.38 (d, J = 3.2 Hz, 1H), 5.89 (ddd, J = 7.6, 10.0, 
17.2 Hz, 1H), 5.84 - 5.73 (m, 1H), 5.46 - 5.36 (m, 1H), 5.03 - 4.88 (m, 3H), 4.82 - 4.70 (m, 
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1H), 4.14 (td, J = 4.0, 15.2 Hz, 1H), 3.99 (s, 1H), 4.03 - 3.96 (m, 1H), 2.90 - 2.74 (m, 2H), 
2.66 - 2.43 (m, 1H), 2.04 (d, J = 13.5 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 141.34, 
135.94, 134.82, 132.20, 130.14, 129.90, 128.96, 126.56, 122.19, 114.19, 111.34, 100.70, 
49.89, 45.72, 41.32, 39.34, 35.45. 
 
 
 
5-bromo-1-(tert-butyldimethylsilyl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.25): In a 
flame-dried 250 mL three- necked round-bottom flask under argon was added a solution of 
6.22 (1.30 g, 2.78 mmol) in dry toluene (10 mL). To this was added distilled furan (2.0 mL, 
27.8 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (2.4 mL, 2.60 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78 oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (20 mL). After 
stirring for 5 minutes, the mixture was diluted with water (20 mL) and extracted with diethyl 
ether (3 x 20 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
purified via column chromatography on silica gel using 5% methyl tert-butyl ether in 
hexanes as eluent to give 6.25 (0.816 g, 78%) as a colorless oil that solidifies at cold freezer 
temperatures. 1H NMR (400MHz, CDCl3): δ 7.37 (s, 1H), 7.25 - 7.22 (dd, J = 2.0, 5.3 Hz, 
1H), 7.17 (d, J = 3.4 Hz, 1H), 7.13 (dd, J = 2.0, 5.3 Hz, 1H), 6.51 (d, J = 3.4 Hz, 1H), 6.31 
(br. s, 1H), 5.96 (br. s, 1H), 1.01 (s, 9H), 0.64 (s, 3H), 0.58 (s, 3H). 13C NMR (101MHz, 
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CDCl3): δ 145.01, 144.36, 142.37, 135.22, 132.59, 132.51, 131.83, 116.96, 113.66, 105.24, 
83.20, 82.81, 26.40, 19.33, -2.12, -2.96.  
 
 
5-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.26): In a flame-dried 100 mL three- 
necked round-bottom flask under argon was added a solution of 6.25 (0.650 g, 1.73 mmol) in 
dry tetrahydrofuran (10 mL). The solution was cooled to 0 oC for 10 min. To this was added 
1.0 M tetrabutylammonium fluoride (TBAF) (3.50 mL, 3.45 mmol) dropwise. Reaction was 
then followed by TLC and showed completion after 5 min. The reaction was then quenched 
by addition of saturated NH4Cl (10 mL). The reaction was then extracted with diethyl ether 
(2 x 10 mL). The combined organic phase was dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude material was then purified via 
column chromatography on silica gel using 30% tert-butyl methyl ether in hexanes as eluent 
to give 6.26 (0.372 g, 98%) of as a foamy white solid. 1H NMR (400MHz, CDCl3): δ 8.32 
(br. s., 1H), 7.38 (s, 1H), 7.21 (dd, J = 1.7, 5.6 Hz, 1H), 7.10 - 7.07 (apparent t, J = 2.4 Hz, 1 
H), 7.04 (dd, J = 1.7, 5.6 Hz, 1H), 6.44 (dd, J = 2.0, 2.9 Hz, 1H), 5.98 (m, 2H). 13C NMR 
(101MHz, CDCl3): δ 144.37, 143.60, 142.67, 133.42, 130.30, 129.16, 126.67, 119.11, 
106.47, 102.41, 83.80, 81.58.  
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1-allyl-5-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.27):. In a flame-dried 100 
mL round-bottom flask under argon was added a solution of 6.26 (124 mg, 0.470 mmol) in 
dry tetrahydrofuran (5 mL). To the solution was added sodium hydride (46.0 mg, 1.88 mmol) 
and catalytic tetrabutylammonium iodide (0.90 mg, 0.002 mmol). The solution was then 
cooled to 0 oC for 10 min. To this was added allyl bromide (0.12 mL, 1.42 mmol) dropwise. 
TLC analysis showed completion after 30 min. The reaction was then quenched by addition 
of saturated NH4Cl (10 mL). The reaction was then extracted with diethyl ether (2 x 5 mL). 
The combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to afford 
6.27  (111 mg, 78%) as a yellowish oil. 1H NMR (400MHz, CDCl3): δ 7.36 (s, 1H), 7.20 (dd, 
J = 2.2, 5.6 Hz, 1H), 7.05 (dd, J = 2.2, 5.6 Hz, 1H), 7.01 (d, J = 3.4 Hz, 1H), 6.40 (d, J = 3.4 
Hz, 1H), 6.18 - 6.16 (m, 1H), 6.01 (td, J = 4.6, 10.2 Hz, 1H), 5.97 - 5.93 (m, 1H), 5.24 (d, J = 
10.2 Hz, 1H), 4.97 - 4.93 (m, 1H), 4.83 (apparent. td, J = 1.9, 4.8 Hz, 1H 1H), 4.72 (td, J = 
2.0, 4.3 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 144.56, 144.26, 143.32, 133.97, 131.21, 
130.99, 129.37, 128.82, 117.04, 116.79, 113.13, 101.88, 82.87, 81.36, 50.12.  
 
 
5-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.28): In a flame-
dried 100 mL round-bottom flask under argon was added a solution of 6.26 (120 mg, 0.460 
mmol) in dry tetrahydrofuran (8 mL). To the solution was added sodium hydride (44.2 mg, 
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1.84 mmol) and catalytic tetrabutylammonium iodide (8.50 mg, 0.023 mmol). The solution 
was then cooled to 0 oC for 10 min. To this was added homo-allyl bromide (4-bromo-1-
butene) (0.14 mL, 1.38 mmol) dropwise. TLC analysis showed completion after 2 h. The 
reaction was then quenched by addition of saturated NH4Cl (20 mL). The reaction was then 
extracted with diethyl ether (2 x 10 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was then purified via column chromatography on silica gel using 50% methyl tert-
butyl ether in hexanes as eluent to afford 6.28  (104 mg, 72%) as a dark brown oil that 
solidifies upon cooling, MP: 83.1-84.9 oC 1H NMR (400MHz, CDCl3): δ 7.35 (s, 1H), 7.24 
(dd, J = 1.8, 5.6 Hz, 1H), 7.15 (dd, J =1.9, 5.4 Hz, 1H), 7.01 (d, J = 3.2 Hz, 1H), 6.36 (d, J = 
3.2 Hz, 1H), 6.24 (dd, J = 1.2, 1.8 Hz, 1H), 5.97 (dd, J = 1.0, 1.9 Hz, 1H), 5.83 - 5.71 (m, 
1H), 5.14 - 5.07 (m, 2H), 4.29 - 4.10 (m, 2H), 2.56 (tq, J = 1.3, 7.1 Hz, 2H). 13C NMR 
(101MHz, CDCl3): δ 144.7, 143.8, 143.0, 133.8, 133.1, 131.1, 130.2, 130.1, 119.5, 118.0, 
106.5, 101.2, 83.5, 82.2, 47.6, 35.3.  
 
 
(2S,9aR)-3-bromo-2-vinyl-7,9a-dihydro-2H-1-oxa-6a-azacyclohepta[jkl]-as-indacene 
(2b): In a 25 mL dry sealed tube was added a solution of 6.27 (0.150 g (0.500 mmol) in 
CH2Cl2 (5 mL). The solution was stirred and purged with argon. To the solution was added 
Grubbs’ first generation catalyst (20.6 mg, 0.025 mmol) and refluxed for 0.5 h. TLC analysis 
showed completion of the reaction. The reaction was cooled to r.t. and the ruthenium 
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scavenger; tris (hydroxymethyl)-phosphine (0.248 g, 2.00 mmol) dissolved in methanol (2 
mL) and Et3N (0.5 mL) was added to the solution and stirred overnight. H2O (5 mL) was 
then added and stirred vigorously for 0.5 h. With the phases separated, the organic layer was 
washed with brine (5 mL) and dried over anhydrous MgSO4. The solution was then filtered 
and concentrated under reduced pressure to afford a dark brown to black oil. 
Chromatography on silica with 40% tert-butyl methyl ether (MTBE) in hexanes as eluents 
afforded 2b (0.062 g, %) as pale yellow oil. 1H NMR (400MHz, CDCl3): δ 7.61 (s, 1H), 7.00 
(d, J = 2.9 Hz, 1H), 6.48 - 6.39 (m, 2H), 6.37 (d, J = 2.9 Hz, 1H), 6.07 (ddd, J = 7.3, 10.1, 
17.2 Hz, 1H), 5.92 - 5.83 (m, 1H), 5.77 (dd, J = 3.4, 7.3 Hz, 1H), 5.58 (td, J = 1.2, 17.1 Hz, 
1H), 5.37 (td, J = 1.1, 10.5 Hz, 1H), 5.11 (ddd, J = 2.4, 5.5, 15.0 Hz, 1H), 4.45 (dd, J = 8.5, 
14.9 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 139.80, 136.87, 131.01, 130.31, 130.03, 
128.89, 124.63, 123.68, 120.05, 118.83, 106.97, 100.28, 87.03, 79.37, 45.15.  
 
 
(2S,10aR,Z)-3-bromo-2-vinyl-2,7,8,10a-tetrahydro-1-oxa-6a-azacycloocta[jkl]-as-
indacene (4b): In a flame dried 25 mL sealed tube was added a solution of 6.28 (100 mg, 
0.320 mmol) in CH2Cl2 (3.8 mL). The solution was stirred and purged with argon. To the 
solution was added Grubbs’s first generation catalyst (13.4 mg, 0.016 mmol) and refluxed for 
0.5 h. TLC analysis showed completion of the reaction. The reaction was cooled to r.t. and 
the ruthenium scavenger; tris (hydroxymethyl)-phosphine (159 mg, 1.28 mmol) dissolved in 
methanol (1.2 mL) and Et3N (0.3 mL) was added to the solution and stirred overnight. H2O 
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(4 mL) was then added and stirred vigorously for 0.5 h. With the phases separated, the 
organic layer was washed with brine (2 x 4 mL) and dried over anhydrous MgSO4. The 
solution was then filtered and concentrated under reduced pressure to afford a dark brown to 
black oil. Chromatography on silica gel with 50% dichloromethane in hexanes as eluents 
afforded 4b (42 mg, 42%) as a pale yellow oil. 1H NMR (400MHz, cdcl3) δ 7.66 (s, 1H), 
7.04 (d, J = 2.9 Hz, 1H), 6.64 - 6.60 (m, 1H), 6.44 (d, J = 2.9 Hz, 1H), 6.09 - 5.96 (m, 2H), 
5.74 (d, J = 7.6 Hz, 1H), 5.55 - 5.45 (m, 2H), 5.31 - 5.26 (m, J = 1.2, 10.2 Hz, 1H), 4.56 - 
4.46 (m, 1H), 4.25 - 4.17 (m, 1H), 2.87 - 2.74 (m, 1H), 2.65 - 2.52 (m, 1H). 13C NMR 
(101MHz, CDCl3): δ 137.7, 134.6, 131.9, 130.8, 129.8, 129.3, 129.4, 124.9, 123.4, 117.4, 
107.0, 101.2, 86.7, 81.0, 45.9, 34.8.  
 
 
5-bromo-1-(tert-butyldimethylsilyl)-6,9-dimethyl-6,9-dihydro-1H-6,9-
epoxybenzo[g]indole (6.29): In a flame-dried 25 mL round-bottom flask under argon was 
added a solution of 6.22 (0.500 g, 1.07 mmol) in dry toluene (10 mL). To this was added 2,5-
dimethyl furan (1.15 mL, 10.7 mmol). The resulting solution was cooled to -78 oC, then 2.5 
M solution of n-butyl lithium (0.86 mL, 2.14 mmol) in hexanes was added dropwise via 
syringe over 15 min. The solution was stirred at -78 oC for 30 min then allowed to slowly 
warm to room temperature. The reaction was then quenched by addition of saturated NH4Cl 
(20 mL). After stirring for 5 minutes, the mixture was diluted with water (20 mL) and 
extracted with diethyl ether (3 x 20 mL). The combined organic phase was dried over 
anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
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material was then purified via column chromatography on silica gel using 10% methyl tert-
butyl ether in hexanes as eluent to give 6.29 (0.315 g, 73%) as a yellowish oil. 1H NMR 
(400MHz, CDCl3): δ 7.26 (s, 1 H), 7.17 (d, J = 3.2 Hz, 1H), 7.07 (d, J = 5.6 Hz, 1H), 6.91 (d, 
J = 5.6 Hz, 1H), 6.44 (d, J = 2.9 Hz, 1H), 2.04 (s, 3H), 2.01 (s, 3H), 0.96 (s, 9H), 0.44 (s, 
3H), 0.09 (s, 3H). 13C NMR (101MHz, CDCl3): δ 148.32, 145.34, 138.91, 136.57, 134.57, 
132.78, 116.53, 112.33, 107.06, 90.25, 87.51, 72.79, 49.45, 27.32, 26.96, 20.01, 19.28, 16.04, 
-0.88, -1.92.  
 
 
5-bromo-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.30): In a flame-dried 
100 mL round-bottom flask under argon was added a solution of 6.29 (0.300 g, 0.744 mmol) 
in dry tetrahydrofuran (8 mL). The solution was cooled to 0 oC for 10 min. To this was added 
1.0 M tetrabutylammonium fluoride (TBAF) (1.50 mL, 1.49 mmol) dropwise. Reaction was 
then followed by TLC and showed completion after 20 min. The reaction was then quenched 
by addition of saturated NH4Cl (10 mL). The reaction was then extracted with diethyl ether 
(2 x 10 mL). The combined organic phase was dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude material was then purified via 
column chromatography on silica gel using 30% tert-butyl methyl ether in hexanes as eluent 
to give 6.30 as a foamy white solid (0.155 g, 72%) MP: 136-139 oC. 1H NMR (400MHz, 
CDCl3): δ 8.01 (br. s, 1H), 7.37 (s, 1H), 7.17 (app. t, J = 2.9 Hz, 1H), 6.96 (d, J = 5.3 Hz, 
1H), 6.89 (d, J = 5.3 Hz, 1H), 6.45 (dd, J = 2.0, 3.4 Hz, 1H), 2.13 (d, J = 8.8 Hz, 6H). 13C 
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NMR (101MHz, CDCl3): δ 148.39, 146.91, 145.05, 137.23, 130.60, 129.04, 126.85, 120.46, 
106.63, 102.28, 92.17, 88.20, 18.02, 16.95.  
 
 
1-allyl-5-bromo-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.31): In a 
flame-dried 100 mL round-bottom flask under argon was added a solution of 6.30 (140 mg, 
0.484 mmol) in dry tetrahydrofuran (10 mL). To the solution was added sodium hydride 
(47.0 mg, 1.94 mmol) and catalytic tetrabutylammonium iodide (0.90 mg, 0.002 mmol). The 
solution was then cooled to 0 oC for 10 min. To this was added allyl bromide (0.13 mL, 1.45 
mmol) dropwise. TLC analysis showed completion after 30 min. The reaction was then 
quenched by addition of saturated NH4Cl (10 mL). The reaction was then extracted with 
diethyl ether (2 x 10 mL). The combined organic phase was dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was 
then purified via column chromatography on silica gel using 40% methyl tert-butyl ether in 
hexanes as eluent to afford 6.31 (111 mg, 78%) as yellowish oil. 1H NMR (400MHz, 
CDCl3): δ 7.37 (s, 1H), 6.97 (d, J = 3.5 Hz, 1H), 6.92 (d, J = 5.3 Hz, 1H), 6.78 (d, J = 5.4 Hz, 
1H), 6.39 (d, J = 3.1 Hz, 1H), 6.00 (tdd, J = 4.0, 10.5, 17.2 Hz, 1H), 5.17 (d, J = 10.2 Hz, 
1H), 5.02 - 4.84 (m, 1H), 4.84 - 4.63 (m, 2H), 2.15 (s, 6H). 13C NMR (101MHz, CDCl3): δ 
148.52, 147.22, 145.82, 138.34, 134.22, 132.36, 132.22, 130.81, 121.44, 116.46, 106.56, 
101.54, 91.09, 89.65, 51.35, 20.45, 18.62.  
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5-bromo-1-(but-3-en-1-yl)-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.32): 
In a flame-dried 50 mL round-bottom flask under argon was added a solution of 6.30 (67 mg, 
0.23 mmol) in dry tetrahydrofuran (5 mL). To the solution was added sodium hydride (22.3 
mg, 0.93 mmol) and catalytic tetrabutylammonium iodide (0.42 mg, 0.001 mmol). The 
solution was then cooled to 0 oC for 10 min. To this was added homo-allyl bromide (4-
bromo-1-butene) (0.1 mL, 0.70 mmol) dropwise. TLC analysis showed starting material 
present even after 2 h. The reaction was then quenched by addition of saturated NH4Cl (5 
mL). The reaction was then extracted with diethyl ether (2 x 5 mL). The combined organic 
phase was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced 
pressure. The crude material was then purified via column chromatography on silica gel 
using 5% methyl tert-butyl ether in hexanes as eluent to afford 6.32 (46 mg, 58%) as a 
yellow oil. 1H NMR (400MHz, CDCl3): δ 7.36 (s, 1H), 6.98 (d, J = 3.2 Hz, 1H), 6.97 (d, J = 
5.3 Hz, 1H), 6.89 (d, J = 5.3 Hz, 1H), 6.34 (d, J = 3.2 Hz, 1H), 5.71 (tdd, J = 6.7, 10.3, 17.0 
Hz, 1H), 5.11 - 5.03 (m, 2H), 4.43 (ddd, J = 5.9, 8.3, 14.3 Hz, 1H), 4.18 - 4.05 (m, 1H), 2.52 
- 2.37 (m, 2H), 2.17 (d, J = 9.1 Hz, 6H). 13C NMR (101MHz, CDCl3): δ 149.03, 146.81, 
145.52, 138.29, 133.75, 132.65, 131.91, 130.44, 121.53, 117.75, 106.54, 101.35, 91.18, 
89.66, 48.69, 35.50, 20.62, 18.67.  
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(2S,9aR)-3-bromo-2,9a-dimethyl-2-vinyl-7,9a-dihydro-2H-1-oxa-6a-azacyclohepta[jkl]-
as-indacene (2c): In a 25 mL dry sealed tube was added a solution of 6.31 (0.500 g 0.150 
mmol) in CH2Cl2 (5 mL). The solution was stirred and purged with argon. To the solution 
was added Grubbs’ first generation catalyst (6.2 mg, 0.008 mmol) and refluxed for 0.5 h. 
TLC analysis showed completion of the reaction. The reaction was cooled to r.t. and the 
ruthenium scavenger; tris (hydroxymethyl)-phosphine (0.079 g, 0.64 mmol) dissolved in 
methanol (1mL) and Et3N (0.1 mL) was added to the solution and stirred overnight. H2O (5 
mL) was then added and stirred vigorously for 0.5 h. With the phases separated, the organic 
layer was washed with brine (5 mL) and dried over anhydrous MgSO4. The solution was then 
filtered and concentrated under reduced pressure to afford a dark brown to black oil. 
Chromatography on silica with 60% dichloromethane in hexanes as eluents afforded 2c 
(0.018 g, 36%) as a yellow oil. 1H NMR (400MHz, CDCl3): δ 7.62 (s, 1H), 7.00 (d, J = 3.3 
Hz, 1H), 6.56 (dd, J=2.9, 11.7 Hz, 1H), 6.39 (d, J = 2.9 Hz, 1H), 6.30 (dd, J = 10.5, 17.0 Hz, 
1H), 5.69 (ddd, J = 4.5, 8.9, 11.7 Hz, 1H), 5.38 (dd, J = 1.6, 17.1 Hz, 1H), 5.20 - 5.12 (m, 
2H), 4.50 (dd, J = 8.8, 15.5 Hz, 1H), 1.90 (br. s., 1H), 1.90 (d, J = 4.4 Hz, 6H). 13C NMR 
(101MHz, CDCl3): δ 144.32, 141.45, 134.24, 130.25, 129.46, 129.24, 128.06, 124.32, 
117.93, 113.80, 106.58, 100.61, 89.40, 84.01, 45.25, 30.66, 26.17.  
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(2S,10aR,Z)-3-bromo-2,10a-dimethyl-2-vinyl-2,7,8,10a-tetrahydro-1-oxa-6a-
azacycloocta[jkl]-as-indacene (4c): In a flame dried 25 mL sealed tube was added a 
solution of 6.32 (50 mg 0.15 mmol) in CH2Cl2 (5 mL). The solution was stirred and purged 
with argon. To the solution was added Grubbs’ first generation catalyst (6.20 mg, 0.007 
mmol) and refluxed for 0.5 h. TLC analysis showed completion of the reaction. The reaction 
was cooled to r.t. and the ruthenium scavenger; tris (hydroxymethyl)-phosphine (72.4 mg, 
0.584 mmol) dissolved in methanol (1.2 mL) and Et3N (0.3 mL) was added to the solution 
and stirred overnight. H2O (5 mL) was then added and stirred vigorously for 0.5 h. With the 
phases separated, the organic layer was washed with brine (2 x 5 mL) and dried over 
anhydrous MgSO4. The solution was then filtered and concentrated under reduced pressure to 
afford a dark brown to black oil. Chromatography on silica with 60% dichloromethane in 
hexanes as eluents afforded 4c (24.6 mg, 49.2%) as a yellow oil. 
 
 
Alternative Syntheses 
	  
1-allyl-5,6,7-tribromo-1H-indole (5.61): In a flame-dried 100 mL round-bottom flask under 
argon was added a solution of 4.84 (1.50 g, 4.24 mmol) in dry tetrahydrofuran (30 mL). To 
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the solution was added sodium hydride (0.407 mg, 17.0 mmol) and catalytic 
tetrabutylammonium iodide (7.83 mg, 0.021 mmol). The solution was then cooled to 0 oC for 
10 min. To this was added allyl bromide (1.10 mL, 12.7 mmol) dropwise. TLC analysis 
showed completion after 30 min. The reaction was then quenched by addition of saturated 
NH4Cl (60 mL). The reaction was then extracted with diethyl ether (3 x 60 mL). The 
combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure. The crude material was then purified via column 
chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to afford 
5.61  (1.50 g, 90.0%) as granular white solid, MP: 107-109 oC. 1H NMR (400MHz, CDCl3): 
δ 7.86 (s, 1H), 7.10 (d, J = 3.2 Hz, 1H), 6.45 (d, J = 3.2 Hz, 1H), 6.04 (tdd, J = 4.9, 10.0, 
17.0 Hz, 1H), 5.18 - 5.13 (m, 3H), 4.76 (d, J =17.9 Hz, 1H). 13C NMR (101MHz, CDCl3): δ 
= 134.59, 133.10, 132.95, 131.25, 124.31, 121.57, 116.46, 115.51, 107.46, 101.57, 50.70. 
 
 
	  
5,6,7-tribromo-1-(but-3-en-1-yl)-1H-indole (5.62): In a flame-dried 100 mL round-bottom 
flask under argon was added a solution of 4.84 (420 mg, 1.19 mmol) in dry tetrahydrofuran 
(10 mL). To the solution was added sodium hydride (114 mg, 4.75 mmol) and catalytic 
tetrabutylammonium iodide (2.20 mg, 0.006 mmol). The solution was then cooled to 0 oC for 
10 min. To this was added homo-allyl bromide (4-bromo-1-butene) (0.36 mL, 3.57 mmol) 
dropwise. The reaction was monitored by TLC analysis which showed starting material even 
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after 4 h. The reaction was then quenched by addition of saturated NH4Cl (10 mL). The 
reaction was then extracted with diethyl ether (2 x 5 mL). The combined organic phase was 
dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude material was then purified via column chromatography on silica gel using 5% 
methyl tert-butyl ether in hexanes as eluent to afford 5.62 (233 mg, 48.0% or 78% based on 
recovered starting material) as yellow oil.	  
	  
	  
1-allyl-5-bromo-6,9-dihydro-1H-6,9-methanobenzo[g]indole (5.64):	  In a flame-dried 1000 
mL three- necked round-bottom flask under argon was added a solution of 5.61 (100 mg, 
0.25 mmol) in dry toluene (8 mL). To this was added cyclopentadiene (0.2 mL, 2.5 mmol). 
The resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyllithium (0.20 mL, 
0.51 mmol) in hexanes was added dropwise via syringe over 15 min. The solution was stirred 
at -78oC for 30 min then allowed to slowly warm to room temperature. The reaction was then 
quenched by addition of saturated NH4Cl (8 mL). After stirring for 5 minutes, the mixture 
was diluted with water (8 mL) and extracted with diethyl ether (3 x 8 mL). The combined 
organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under 
reduced pressure. The crude material was then purified via column chromatography on silica 
gel using 5% methyl tert-butyl ether in hexanes as eluent to give 5.64 (57 mg, 76%) as 
colorless oil that solidifies at cold freezer temperatures.  
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5-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-methanobenzo[g]indole (5.66): In a 
flame-dried 100 mL three- necked round-bottom flask under argon was added a solution of 
5.62 (100 mg, 0.245 mmol) in dry toluene (10 mL). To this was added cyclopentadiene (0.20 
mL, 2.45 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (0.22 mL, 0.54 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78 oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (10 mL). After 
stirring for 5 minutes, the mixture was diluted with water (20 mL) and extracted with diethyl 
ether (3 x 10 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
purified via column chromatography on silica gel using 5% methyl tert-butyl ether in 
hexanes as eluent to give 5.66 (49 mg, 64%) as colorless oil that solidifies at cold freezer 
temperatures. 	  
	  
1-allyl-5-bromo-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.27):	  In a flame-dried 250 mL 
three- necked round-bottom flask under argon was added a solution of 5.61 (200 mg, 0.510 
mmol) in dry toluene (10 mL). To this was added distilled furan (2.0 mL, 27.2 mmol). The 
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resulting solution was cooled to -78 oC, then 2.5 M solution of n-butyllithium (0.41 mL, 1.02 
mmol) in hexanes was added dropwise via syringe over 15 min. The solution was stirred at -
78oC for 30 min then allowed to slowly warm to room temperature. The reaction was then 
quenched by addition of saturated NH4Cl (10 mL). After stirring for 5 minutes, the mixture 
was diluted with water (20 mL) and extracted with diethyl ether (3 x 10 mL). The combined 
organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under 
reduced pressure. The crude material was then purified via column chromatography on silica 
gel using 5% methyl tert-butyl ether in hexanes as eluent to give 6.27 (0.12 g, 78%) as 
colorless oil that solidified at cold freezer temperatures.  
 
 
5-bromo-1-(but-3-en-1-yl)-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.28): In a flame-
dried 250 mL three- necked round-bottom flask under argon was added a solution of 5.62 
(200 mg, 0.490 mmol) in dry toluene (10 mL). To this was added distilled furan (3.60 mL, 
49.0 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (0.40 mL, 0.490 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78 oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (20 mL). After 
stirring for 5 minutes, the mixture was diluted with water (20 mL) and extracted with diethyl 
ether (3 x 20 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
  106 
purified via column chromatography on silica gel using 5% methyl tert-butyl ether in 
hexanes as eluent to give 6.28 (0.96 g, 62%) as colorless oil that solidifies at cold freezer 
temperatures.  
 
	  
1-allyl-5-bromo-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.31):	   In a 
flame-dried 250 mL three- necked round-bottom flask under argon was added a solution of 
5.61 (430 mg, 1.10 mmol) in dry toluene (11 mL). To this was added 2,5-dimethyl furan 
(1.20 mL, 10.9 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (0.9 mL, 2.2 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78 oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (10 mL). After 
stirring for 5 minutes, the mixture was diluted with water (10 mL) and extracted with diethyl 
ether (3 x 10 mL). The combined organic phase was dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude material was then 
purified via column chromatography on silica gel using 5% methyl tert-butyl ether in 
hexanes as eluent to give 6.31 (0.28 g, 77%) as yellow oil.  
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5-bromo-1-(but-3-en-1-yl)-6,9-dimethyl-6,9-dihydro-1H-6,9-epoxybenzo[g]indole (6.32): 
In a flame-dried 10 mL three- necked round-bottom flask under argon was added a solution 
of 5.62 (48 mg, 0.12 mmol) in dry toluene (5 mL). To this was added 2,5-dimethyl furan 
(0.13 mL, 1.18 mmol). The resulting solution was cooled to -78 oC, then 2.5 M solution of n-
butyllithium (0.10 mL, 0.26 mmol) in hexanes was added dropwise via syringe over 15 min. 
The solution was stirred at -78 oC for 30 min then allowed to slowly warm to room 
temperature. The reaction was then quenched by addition of saturated NH4Cl (5 mL). After 
stirring for 5 minutes, the mixture was diluted with water (5 mL) and extracted with diethyl 
ether (3 x 5 mL). The combined organic phase was dried over anhydrous magnesium sulfate, 
filtered and concentrated under reduced pressure. The crude material was then purified via 
column chromatography on silica gel using 5% methyl tert-butyl ether in hexanes as eluent to 
give 6.32 (0.028 g, 68%) as yellow oil.  
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Spectra 
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CONCLUSIONS 
The synthesis of unique polycyclic benzannulated scaffolds was accomplished via Bartoli 
indole synthesis and Leimgruber-Batcho synthesis. These scaffolds were demonstrated to 
possess immense potential in library development due to their several points of diversity 
useful in introducing other functional groups essential for library development. 
Several of these scaffolds have demonstrated their ability to undergo Buchwald-Hartwig and 
Suzuki-Miyaura cross-couplings on either the C4 or C5 aryl bromide bonds which bespeaks 
of their versatility and application in library development, these results will be included in a 
manuscript that is in preparation. 
In summary, we have produced the first benzannulated and bridged medium ring small 
compound library inspired by the natural products; trikentrin and herbindole benzannulated 
natural products as well as a new feature of the rare medium ring inspired by the powerful 
antitumor agent marine natural product octalactins A. 
Overall, these scaffolds features a diverse topology with stereogenic centers, unique ring 
systems and other functionalities commensurate with pharmaceutically desired traits, hence 
their success in drug development is highly anticipated. 
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